Tokushima University / Educator and Researcher Directory --- Nakataki, Masahito

Field of Study

○	Medicine

Subject of Study

○

Book / Paper

Book:

1.	Masahito Nakataki : 診療と検査, 株式会社中外医学社, Jan. 2021.
2.	Masahito Nakataki : CHAPTER 11 てんかん, 株式会社中外医学社, Jun. 2016.
3.	Masahito Nakataki and Shinya Watanabe : てんかん, 株式会社中外医学社, Jun. 2015.
4.	Masahito Nakataki : てんかん, 株式会社中外医学社, Mar. 2011.

Academic Paper (Judged Full Paper):

1.	Keita Kiuchi, Hidehiro Umehara, Koushi Irizawa, XIN KANG, Masahito Nakataki, Minoru Yoshida, Shusuke Numata and Kazuyuki Matsumoto : An Exploratory Study of the Potential of Online Counseling for University Students by a Human-Operated Avatar Counselor, Healthcare, Vol.12, No.1287, 2024. (Summary) Recently, the use of digital technologies, such as avatars and virtual reality, has been increasingly explored to address university students mental health issues. However, there is limited research on the advantages and disadvantages of counselors using avatars in online video counseling. Herein, 25 university students were enrolled in a pilot online counseling session with a human counselor-controlled avatar, and asked about their emotional experiences and impressions of the avatar and to provide qualitative feedback on their communication experience. Positive emotions during the session were associated with impressions of the avatars intelligence and likeability. The anthropomorphism, animacy, likeability, and intelligent impressions of the avatar were interrelated, indicating that the avatars smile and the counselors expertise in empathy and approval may have contributed to these impressions. However, no associations were observed between participant experiences and their prior communication with avatars, or between participant experiences and their gender or the perceived gender of the avatar. Accordingly, recommendations for future practice and research are provided. Accumulating practical and empirical findings on the effectiveness of human-operated avatar counselors is crucial for addressing university students mental health issues. (Keyword) avatar counseling / human-operated avatars / university students / digital mental health / empathy / communication / anthropomorphism / animacy / likeability / perceived intelligence (Link to Publication Site) ● Publication site (DOI): 10.3390/healthcare12131287 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38998822 ● Summary page in Scopus @ Elsevier: 2-s2.0-85198398651 (DOI: 10.3390/healthcare12131287, PubMed: 38998822, Elsevier: Scopus)
2.	Tomoya Takeda, Masahito Nakataki, Hidehiro Umehara and Shusuke Numata : Associations between negative and positive automatic thoughts and clinical variables in patients with schizophrenia., Schizophrenia Research. Cognition, Vol.35, 2023. (Summary) This study investigated the relationships between negative and positive automatic thoughts and clinical variables in patients with schizophrenia. The participants included 36 patients with schizophrenia (male = 16; female = 20; age = 42.86 ± 9.40) who were outpatients in the Department of Psychiatry at Tokushima University Hospital. We used the Automatic Thoughts Questionnaire-Revised (ATQ-R), Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), and Brief Assessment of Cognition in Schizophrenia (BACS) to assess negative and positive automatic thoughts, positive and negative symptoms, depressive symptoms, and neurocognition, respectively. Spearman rank correlation coefficients were calculated to determine the relationships between negative and positive automatic thoughts and clinical variables. No relationship was observed between negative and positive automatic thoughts. Negative automatic thoughts were related to depressive symptoms. Positive automatic thoughts were related to neurocognition. We therefore surmise that each automatic thought might have different clinical features and outcomes, and should therefore be treated accordingly. (Tokushima University Institutional Repository) ● Metadata: 119442 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.scog.2023.100298 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38115993 ● Search Scopus @ Elsevier (PMID): 38115993 ● Search Scopus @ Elsevier (DOI): 10.1016/j.scog.2023.100298 (Tokushima University Institutional Repository: 119442, DOI: 10.1016/j.scog.2023.100298, PubMed: 38115993)
3.	Junya Matsumoto, Masaki Fukunaga, Kenichiro Miura, Kiyotaka Nemoto, Naohiro Okada, Naoki Hashimoto, Kentaro Morita, Daisuke Koshiyama, Kazutaka Ohi, Tsutomu Takahashi, Michihiko Koeda, Hidenaga Yamamori, Michiko Fujimoto, Yuka Yasuda, Satsuki Ito, Ryuichi Yamazaki, Naomi Hasegawa, Hisashi Narita, Satoshi Yokoyama, Ryo Mishima, Jun Miyata, Yuko Kobayashi, Daiki Sasabayashi, Kenichiro Harada, Maeri Yamamoto, Yoji Hirano, Takashi Itahashi, Masahito Nakataki, Ryu-Ichiro Hashimoto, K Khin Tha, Shinsuke Koike, Toshio Matsubara, Go Okada, Reiji Yoshimura, Osamu Abe, M Erp Theo G van, A Jessica Turner, Neda Jahanshad, M Paul Thompson, Toshiaki Onitsuka, Yoshiyuki Watanabe, Koji Matsuo, Hidenori Yamasue, Yasumasa Okamoto, Michio Suzuki, Norio Ozaki, Kiyoto Kasai and Ryota Hashimoto : Cerebral cortical structural alteration patterns across four major psychiatric disorders in 5549 individuals., Molecular Psychiatry, Vol.28, No.11, 4915-4923, 2023. (Summary) According to the operational diagnostic criteria, psychiatric disorders such as schizophrenia (SZ), bipolar disorder (BD), major depressive disorder (MDD), and autism spectrum disorder (ASD) are classified based on symptoms. While its cluster of symptoms defines each of these psychiatric disorders, there is also an overlap in symptoms between the disorders. We hypothesized that there are also similarities and differences in cortical structural neuroimaging features among these psychiatric disorders. T1-weighted magnetic resonance imaging scans were performed for 5,549 subjects recruited from 14 sites. Effect sizes were determined using a linear regression model within each protocol, and these effect sizes were meta-analyzed. The similarity of the differences in cortical thickness and surface area of each disorder group was calculated using cosine similarity, which was calculated from the effect sizes of each cortical regions. The thinnest cortex was found in SZ, followed by BD and MDD. The cosine similarity values between disorders were 0.943 for SZ and BD, 0.959 for SZ and MDD, and 0.943 for BD and MDD, which indicated that a common pattern of cortical thickness alterations was found among SZ, BD, and MDD. Additionally, a generally smaller cortical surface area was found in SZ and MDD than in BD, and the effect was larger in SZ. The cosine similarity values between disorders were 0.945 for SZ and MDD, 0.867 for SZ and ASD, and 0.811 for MDD and ASD, which indicated a common pattern of cortical surface area alterations among SZ, MDD, and ASD. Patterns of alterations in cortical thickness and surface area were revealed in the four major psychiatric disorders. To our knowledge, this is the first report of a cross-disorder analysis conducted on four major psychiatric disorders. Cross-disorder brain imaging research can help to advance our understanding of the pathogenesis of psychiatric disorders and common symptoms. (Keyword) Humans / Depressive Disorder, Major / Autism Spectrum Disorder / Bipolar Disorder / Mental Disorders / Cerebral Cortex / magnetic resonance imaging (Link to Publication Site) ● Publication site (DOI): 10.1038/s41380-023-02224-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37596354 ● Search Scopus @ Elsevier (PMID): 37596354 ● Search Scopus @ Elsevier (DOI): 10.1038/s41380-023-02224-7 (DOI: 10.1038/s41380-023-02224-7, PubMed: 37596354)
4.	Naohiro Okada, Masaki Fukunaga, Kenichiro Miura, Kiyotaka Nemoto, Junya Matsumoto, Naoki Hashimoto, Masahiro Kiyota, Kentaro Morita, Daisuke Koshiyama, Kazutaka Ohi, Tsutomu Takahashi, Michihiko Koeda, Hidenaga Yamamori, Michiko Fujimoto, Yuka Yasuda, Naomi Hasegawa, Hisashi Narita, Satoshi Yokoyama, Ryo Mishima, Takahiko Kawashima, Yuko Kobayashi, Daiki Sasabayashi, Kenichiro Harada, Maeri Yamamoto, Yoji Hirano, Takashi Itahashi, Masahito Nakataki, Ryu-Ichiro Hashimoto, K Khin Tha, Shinsuke Koike, Toshio Matsubara, Go Okada, M Erp Theo G van, Neda Jahanshad, Reiji Yoshimura, Osamu Abe, Toshiaki Onitsuka, Yoshiyuki Watanabe, Koji Matsuo, Hidenori Yamasue, Yasumasa Okamoto, Michio Suzuki, A Jessica Turner, M Paul Thompson, Norio Ozaki, Kiyoto Kasai and Ryota Hashimoto : Subcortical volumetric alterations in four major psychiatric disorders: a mega-analysis study of 5604 subjects and a volumetric data-driven approach for classification., Molecular Psychiatry, Vol.28, No.12, 5206-5216, 2023. (Summary) Differential diagnosis is sometimes difficult in practical psychiatric settings, in terms of using the current diagnostic system based on presenting symptoms and signs. The creation of a novel diagnostic system using objective biomarkers is expected to take place. Neuroimaging studies and others reported that subcortical brain structures are the hubs for various psycho-behavioral functions, while there are so far no neuroimaging data-driven clinical criteria overcoming limitations of the current diagnostic system, which would reflect cognitive/social functioning. Prior to the main analysis, we conducted a large-scale multisite study of subcortical volumetric and lateralization alterations in schizophrenia, bipolar disorder, major depressive disorder, and autism spectrum disorder using T1-weighted images of 5604 subjects (3078 controls and 2526 patients). We demonstrated larger lateral ventricles volume in schizophrenia, bipolar disorder, and major depressive disorder, smaller hippocampus volume in schizophrenia and bipolar disorder, and schizophrenia-specific smaller amygdala, thalamus, and accumbens volumes and larger caudate, putamen, and pallidum volumes. In addition, we observed a leftward alteration of lateralization for pallidum volume specifically in schizophrenia. Moreover, as our main objective, we clustered the 5,604 subjects based on subcortical volumes, and explored whether data-driven clustering results can explain cognitive/social functioning in the subcohorts. We showed a four-biotype classification, namely extremely (Brain Biotype [BB] 1) and moderately smaller limbic regions (BB2), larger basal ganglia (BB3), and normal volumes (BB4), being associated with cognitive/social functioning. Specifically, BB1 and BB2-3 were associated with severe and mild cognitive/social impairment, respectively, while BB4 was characterized by normal cognitive/social functioning. Our results may lead to the future creation of novel biological data-driven psychiatric diagnostic criteria, which may be expected to be useful for prediction or therapeutic selection. (Tokushima University Institutional Repository) ● Metadata: 119524 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41380-023-02141-9 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37537281 ● Search Scopus @ Elsevier (PMID): 37537281 ● Search Scopus @ Elsevier (DOI): 10.1038/s41380-023-02141-9 (Tokushima University Institutional Repository: 119524, DOI: 10.1038/s41380-023-02141-9, PubMed: 37537281)
5.	Taku Matsuda, Ryoma Morigaki, Yuki Matsumoto, Hideo Mure, Kazuhisa Miyake, Masahito Nakataki, Masafumi Harada and Yasushi Takagi : Obsessivecompulsive symptoms are negatively correlated with motor severity in patients with generalized dystonia, Scientific Reports, Vol.12, No.1, 20350, 2022. (Summary) We aimed to clarify the correlations between motor symptoms and obsessive-compulsive symptoms and between the volumes of basal ganglia components and obsessive-compulsive symptoms. We retrospectively included 14 patients with medically intractable, moderate and severe generalized dystonia. The Burke-Fahn-Marsden Dystonia Rating Scale and Maudsley Obsessional Compulsive Inventory were used to evaluate the severity of dystonia and obsessive-compulsive symptoms, respectively. Patients with generalized dystonia were divided into two groups; patients whose Maudsley Obsessional Compulsive Inventory score was lower than 13 (Group 1) and 13 or more (Group 2). Additionally, the total Maudsley Obsessional Compulsive Inventory scores in patients with dystonia were significantly higher than normal volunteers' scores (p = 0.025). Unexpectedly, Group 2 (high Maudsley Obsessional Compulsive Inventory scores) showed milder motor symptoms than Group 1 (low Maudsley Obsessional Compulsive Inventory scores) (p = 0.016). "Checking" rituals had a strong and significant negative correlation with the Burke-Fahn-Marsden Dystonia Rating Scale (ϱ = - 0.71, p = 0.024) and a strong positive correlation with the volumes of both sides of the nucleus accumbens (right: ϱ = 0.72, p = 0.023; left: ϱ = 0.70, p = 0.034). Our results may provide insights into the pathogenesis of obsessive-compulsive disorder and dystonia. (Keyword) Humans / Dystonia / Retrospective Studies / Dystonic Disorders / Heredodegenerative Disorders, Nervous System (Link to Publication Site) ● Publication site (DOI): 10.1038/s41598-022-24826-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36437372 ● Search Scopus @ Elsevier (PMID): 36437372 ● Search Scopus @ Elsevier (DOI): 10.1038/s41598-022-24826-x (DOI: 10.1038/s41598-022-24826-x, PubMed: 36437372)
6.	Kazuyoshi Ogasawara, Shusuke Numata, Naomi Hasegawa, Masahito Nakataki, Manabu Makinodan, Kazutaka Ohi, Masahiro Takeshima, Takashi Tsuboi, Naoki Hashimoto, Toshiaki Onitsuka, Hiroyuki Muraoka, Hikaru Hori, Kayo Ichihashi, Takahiko Inagaki, Norio Yasui-Furukori, Akitoyo Hishimoto, Nobuhiro Sugiyama, Kentaro Fukumoto, Tatsuya Nagasawa, Junya Matsumoto, Yoshikazu Takaesu, Ryuji Furihata, Kiyotaka Nemoto, Toshinori Nakamura, Masahide Usami, Kenichiro Miura, Michiko Fujimoto, Hiromi Tagata, Hisashi Yamada, Hiroshi Komatsu, Shinichiro Ochi, Kiyokazu Atake, Eiichi Katsumoto, Mikio Kido, Taishiro Kishimoto, Taro Suwa, Satoshi Yamamura, Junichi Iga, Hitoshi Iida, Ken Inada, Koichiro Watanabe and Ryota Hashimoto : Subjective assessment of participants in education programs on clinical practice guidelines in the field of psychiatry., Neuropsychopharmacology Reports, Vol.42, No.2, 221-225, 2022. (Summary) The Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE) project, which is a nationwide dissemination and implementation program for clinical practice guidelines (CPGs) in the field of psychiatry, is currently ongoing. In the current study, a subjective assessment of the participants in the EGUIDE programs was assessed using a questionnaire. Then, the relationships between the subjective assessment, the characteristics of the participants, and the clinical knowledge of the CPGs were evaluated. More than 90% of the participants gave a high rating for the components of content, recommendation, knowledge, skill, and adherence, but not for the component of confidence. A positive correlation was found between years of professional experience and the score of confidence. These results suggest that it may be necessary to apply the knowledge and skills of CPGs obtained in the education programs into practice to increase confidence in the proper use of psychiatric therapies based on CPGs. (Keyword) Humans / psychiatry / Surveys and Questionnaires (Tokushima University Institutional Repository) ● Metadata: 118960 (Link to Publication Site) ● Publication site (DOI): 10.1002/npr2.12245 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35272393 ● Search Scopus @ Elsevier (PMID): 35272393 ● Search Scopus @ Elsevier (DOI): 10.1002/npr2.12245 (Tokushima University Institutional Repository: 118960, DOI: 10.1002/npr2.12245, PubMed: 35272393)
7.	Shusuke Numata, Masahito Nakataki, Naomi Hasegawa, Yoshikazu Takaesu, Masahiro Takeshima, Toshiaki Onitsuka, Toshinori Nakamura, Reon Edagawa, Hiroaki Edo, Kenichiro Miura, Junya Matsumoto, Norio Yasui-Furukori, Taishiro Kishimoto, Hikaru Hori, Takashi Tsuboi, Yuka Yasuda, Ryuji Furihata, Hiroyuki Muraoka, Shinichiro Ochi, Tatsuya Nagasawa, Yoshitaka Kyou, Atsunobu Murata, Eiichi Katsumoto, Kazutaka Ohi, Akitoyo Hishimoto, Ken Inada, Koichiro Watanabe and Ryota Hashimoto : Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study., Neuropsychopharmacology Reports, Vol.41, No.2, 199-206, 2021. (Summary) We reported improvements in clinical knowledge of CPGs after the EGUIDE program in the 2017 group following revision of the lecture materials based on results from the 2016 group. These attempts to improve the degree of understanding of CPGs may facilitate the successful dissemination and implementation of psychiatric guidelines in everyday practice. (Keyword) Depressive Disorder, Major / Humans / psychiatry / schizophrenia (Tokushima University Institutional Repository) ● Metadata: 117577 (Link to Publication Site) ● Publication site (DOI): 10.1002/npr2.12173 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33704931 ● Search Scopus @ Elsevier (PMID): 33704931 ● Search Scopus @ Elsevier (DOI): 10.1002/npr2.12173 (Tokushima University Institutional Repository: 117577, DOI: 10.1002/npr2.12173, PubMed: 33704931)
8.	Chise Ueoka, Masahito Nakataki, Yoshinori Ueoka, Atsuko Miyazaki, Saki Taniguchi and Tetsuro Ohmori : An attempt to analyze the longitudinal psychological state of cancer patients in the active treatment stage., The Journal of Medical Investigation : JMI, Vol.68, No.1.2, 148-153, 2021. (Summary) The psychological state and changes over time of cancer patients in the active treatment stage were classified into emotions by the speech and behavior of the patient described in the medical record article of the cancer psychological interview record, and the analysis of the "emotional state map" was attempted. In all cases, positive / negative emotions were mixed and appeared with variation, but a relatively large number of positive emotions, including <joy>, <relief>, and <liking>, were manifested, and the same was true in patients who experienced stressful treatment events. In the background, the existence of appropriate support from medical professionals and psychological characteristics peculiar to the stage of active treatment was inferred, such as the active treatment of the target patient, the hospitalization environment in which mental and physical pain promptly appealed to medical professionals, and the influence of psychological interviews. Cancer patients during active treatment perceived and expressed changes in the body and pain caused by the disease, and after responses from medical professionals and family members, they were conscious of their physical condition and emotions. It is suggested that this analysis method helps to objectively understand and explain the invisible and ever-changing psychological state of cancer patients in the active treatment stage. J. Med. Invest. 68 : 148-153, February, 2021. (Tokushima University Institutional Repository) ● Metadata: 115935 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.148 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33994460 ● Search Scopus @ Elsevier (PMID): 33994460 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.148 (Tokushima University Institutional Repository: 115935, DOI: 10.2152/jmi.68.148, PubMed: 33994460)
9.	Chigusa Uchiumi, Hiroshi Kato, Motohiro Ishida, Masahito Nakataki and Tetsuro Ohmori : Peritraumatic reactions, PTSD symptoms, and pain : A study of train disasters in Japan., The Journal of Medical Investigation : JMI, Vol.68, No.1.2, 85-89, 2021. (Summary) Objective : The purpose of this study was to examine the relationship between peritraumatic reactions, posttraumatic stress disorder (PTSD) symptoms, and pain in people injured in train disasters. Methods : The participants were injured in a train crash in Japan that left more than 100 dead. There were 218 participants in the analysis, with a mean age of 37.50 ± 14.67 years. Peritraumatic reactions were assessed using the Peritraumatic Distress Inventory. PTSD symptoms were evaluated using the Impact of Event Scale-Revised Japanese-language version. Pain was measured using the Visual Analog Scale. Results : Peritraumatic reactions did not directly affect PTSD symptoms but were found to be associated via latent variables. Regarding pain and PTSD symptoms, intrusive memories were more associated with pain than other symptoms were. There was an associative path from intrusion to pain, but no such path from pain to intrusion. Conclusions : Our results suggest that a therapeutic approach to intrusion may be effective in ameliorating the pain caused by injury. Future research should examine integrated treatment approaches for both PTSD and pain, rather than just for aspects of PTSD. J. Med. Invest. 68 : 85-89, February, 2021. (Tokushima University Institutional Repository) ● Metadata: 115626 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.85 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33994485 ● Search Scopus @ Elsevier (PMID): 33994485 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.85 (Tokushima University Institutional Repository: 115626, DOI: 10.2152/jmi.68.85, PubMed: 33994485)
10.	Ryoma Morigaki, Ryosuke Miyamoto, Hideo Mure, Koji Fujita, Taku Matsuda, Yoko Yamamoto, Masahito Nakataki, Tetsuya Okahisa, Yuki Matsumoto, Kazuhisa Miyake, Nobuaki Yamamoto, Ryuji Kaji, Yasushi Takagi and Satoshi Goto : Can Pallidal Deep Brain Stimulation Rescue Borderline Dystonia? Possible Coexistence of Functional (Psychogenic) and Organic Components., Brain Sciences, Vol.10, No.9, 636, 2020. (Summary) The diagnosis and treatment of functional movement disorders are challenging for clinicians who manage patients with movement disorders. The borderline between functional and organic dystonia is often ambiguous. Patients with functional dystonia are poor responders to pallidal deep brain stimulation (DBS) and are not good candidates for DBS surgery. Thus, if patients with medically refractory dystonia have functional features, they are usually left untreated with DBS surgery. In order to investigate the outcome of functional dystonia in response to pallidal DBS surgery, we retrospectively included five patients with this condition. Their dystonia was diagnosed as organic by dystonia specialists and also as functional according to the Fahn and Williams criteria or the Gupta and Lang Proposed Revisions. Microelectrode recordings in the globus pallidus internus of all patients showed a cell-firing pattern of bursting with interburst intervals, which is considered typical of organic dystonia. Although their clinical course after DBS surgery was incongruent to organic dystonia, the outcome was good. Our results question the possibility to clearly differentiate functional dystonia from organic dystonia. We hypothesized that functional dystonia can coexist with organic dystonia, and that medically intractable dystonia with combined functional and organic features can be successfully treated by DBS surgery. (Tokushima University Institutional Repository) ● Metadata: 116502 (Link to Publication Site) ● Publication site (DOI): 10.3390/brainsci10090636 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32942724 ● Search Scopus @ Elsevier (PMID): 32942724 ● Search Scopus @ Elsevier (DOI): 10.3390/brainsci10090636 (Tokushima University Institutional Repository: 116502, DOI: 10.3390/brainsci10090636, PubMed: 32942724)
11.	Yukiko Tomioka, Makoto Kinoshita, Hidehiro Umehara, Tomohiko Nakayama, Shinya Watanabe, Masahito Nakataki, Shusuke Numata and Tetsuro Ohmori : Association between serum folate levels and schizophrenia based on sex., Psychiatry and Clinical Neurosciences, Vol.74, No.9, 466-471, 2020. (Summary) Our findings suggest that: (i) a low serum folate level may be associated with schizophrenia regardless of sex; and (ii) folate administration may be beneficial for the treatment of schizophrenia. In schizophrenic patients with low serum folate levels, folate administration might result in improvements in high tHcy and an increase in low vitamin B6 levels. (Tokushima University Institutional Repository) ● Metadata: 115397 (Link to Publication Site) ● Publication site (DOI): 10.1111/pcn.13074 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32445495 ● Search Scopus @ Elsevier (PMID): 32445495 ● Search Scopus @ Elsevier (DOI): 10.1111/pcn.13074 (Tokushima University Institutional Repository: 115397, DOI: 10.1111/pcn.13074, PubMed: 32445495)
12.	D Koshiyama, M Fukunaga, N Okada, K Morita, K Nemoto, K Usui, H Yamamori, Y Yasuda, M Fujimoto, N Kudo, H Azechi, Y Watanabe, N Hashimoto, H Narita, I Kusumi, K Ohi, T Shimada, Y Kataoka, M Yamamoto, N Ozaki, G Okada, Y Okamoto, K Harada, K Matsuo, H Yamasue, O Abe, R Hashimoto, T Takahashi, T Hori, Masahito Nakataki, T Onitsuka, L Holleran, N Jahanshad, TGM Erp van, J Turner, G Donohoe, PM Thompson, K Kasai and R Hashimoto : White matter microstructural alterations across four major psychiatric disorders: mega-analysis study in 2937 individuals., Molecular Psychiatry, Vol.25, No.4, 883-895, 2020. (Summary) Identifying both the commonalities and differences in brain structures among psychiatric disorders is important for understanding the pathophysiology. Recently, the ENIGMA-Schizophrenia DTI Working Group performed a large-scale meta-analysis and reported widespread white matter microstructural alterations in schizophrenia; however, no similar cross-disorder study has been carried out to date. Here, we conducted mega-analyses comparing white matter microstructural differences between healthy comparison subjects (HCS; N = 1506) and patients with schizophrenia (N = 696), bipolar disorder (N = 211), autism spectrum disorder (N = 126), or major depressive disorder (N = 398; total N = 2937 from 12 sites). In comparison with HCS, we found that schizophrenia, bipolar disorder, and autism spectrum disorder share similar white matter microstructural differences in the body of the corpus callosum; schizophrenia and bipolar disorder featured comparable changes in the limbic system, such as the fornix and cingulum. By comparison, alterations in tracts connecting neocortical areas, such as the uncinate fasciculus, were observed only in schizophrenia. No significant difference was found in major depressive disorder. In a direct comparison between schizophrenia and bipolar disorder, there were no significant differences. Significant differences between schizophrenia/bipolar disorder and major depressive disorder were found in the limbic system, which were similar to the differences in schizophrenia and bipolar disorder relative to HCS. While schizophrenia and bipolar disorder may have similar pathological characteristics, the biological characteristics of major depressive disorder may be close to those of HCS. Our findings provide insights into nosology and encourage further investigations of shared and unique pathophysiology of psychiatric disorders. (Tokushima University Institutional Repository) ● Metadata: 115601 (Link to Publication Site) ● Publication site (DOI): 10.1038/s41380-019-0553-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 31780770 ● Search Scopus @ Elsevier (PMID): 31780770 ● Search Scopus @ Elsevier (DOI): 10.1038/s41380-019-0553-7 (Tokushima University Institutional Repository: 115601, DOI: 10.1038/s41380-019-0553-7, PubMed: 31780770)
13.	S Schwab, A Federspiel, Y Morishima, Masahito Nakataki, W Strik, R Wiest, M Heinrichs, D Quervain de and LM Soravia : Glucocorticoids and cortical decoding in the phobic brain., Psychiatry Research. Neuroimaging, Vol.31, No.300, 111066, 2020. (Summary) Glucocorticoids reduce phobic fear in anxiety disorders and enhance psychotherapy, possibly by reducing the retrieval of fear memories and enhancing the consolidation of new corrective memories. Glucocorticoid signaling in the basolateral amygdala can influence connected fear and memory-related cortical regions, but this is not fully understood. Previous studies investigated specific pathways moderated by glucocorticoids, for example, visual-temporal pathways; however, these analyses were limited to a-priori selected regions. Here, we performed whole-brain pattern analysis to localize phobic stimulus decoding related to the fear-reducing effect of glucocorticoids. We reanalyzed functional magnetic resonance imaging (fMRI) data from a previously published study with spider-phobic patients and healthy controls. The patients received glucocorticoids or a placebo before the exposure to spider images. There was moderate evidence that patients with phobia had higher decoding of phobic content in the anterior cingulate cortex (ACC) and the left and right anterior insula compared to controls. Decoding in the ACC and the right insula showed strong evidence for correlation with experienced fear. Patients with cortisol reported a reduction of fear by 10-13%; however, there was only weak evidence for changes in neural decoding compared to placebo which was found in the precuneus, the opercular cortex, and the left cerebellum. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.pscychresns.2020.111066 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32244111 ● Search Scopus @ Elsevier (PMID): 32244111 ● Search Scopus @ Elsevier (DOI): 10.1016/j.pscychresns.2020.111066 (DOI: 10.1016/j.pscychresns.2020.111066, PubMed: 32244111)
14.	Takeo Tominaga, Masahito Tomotake, Tomoya Takeda, Yoshinori Ueoka, Tsunehiko Tanaka, Shinya Watanabe, Naomi Kameoka, Masahito Nakataki, Shusuke Numata, Yumiko Izaki, Satsuki Sumitani, Hiroko Kubo, Yasuhiro Kaneda and Tetsuro Ohmori : Predictors of life skills in people with schizophrenia, The Journal of Medical Investigation : JMI, Vol.67, No.1,2, 75-82, 2020. (Summary) Objective : The purpose of the present study is to examine clinical factors related to life skills in people with schizophrenia. Method : The participants were 51 stabilized outpatients with schizophrenia. Their mean age was 38.91 (SD = 10.73) years. Life skills were assessed using the Life skills profile (LSP). Cognitive function was evaluated with the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB). Clinical symptoms were assessed using the Positive and Negative Syndrome scale (PANSS), the Calgary Depression Scale for Schizophrenia (CDSS) and the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS). Results : Cognitive function was not correlated with the LSP scores at all. Among clinical symptoms, scores of the PANSS positive and negative syndrome scales, the CDSS, and the DIEPSS had negative correlations with the LSP total score and the subscales. Stepwise regression analyses showed that the CDSS and PANSS negative syndrome scale scores were independent predictors of the LSP total score and two of the subscales. Conclusions : These results indicate that cognitive function is not associated with life skills but clinical symptoms such as depressive and negative symptoms have considerable impacts on life skills in people with schizophrenia. J. Med. Invest. 67 : 75-82, February, 2020. (Tokushima University Institutional Repository) ● Metadata: 114756 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.67.75 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32378622 ● Summary page in Scopus @ Elsevier: 2-s2.0-85084203721 (Tokushima University Institutional Repository: 114756, DOI: 10.2152/jmi.67.75, PubMed: 32378622, Elsevier: Scopus)
15.	Chikako Kane, Masahito Tomotake, Hamatani Sayo, Shin-ichi Chiba, Naomi Kameoka, Shinya Watanabe, Masahito Nakataki, Shusuke Numata and Tetsuro Ohmori : Clinical factors influencing resilience in patients with anorexia nervosa, Neuropsychiatric Disease and Treatment, Vol.15, 391-395, 2019. (Summary) This study was to elucidate clinical factors influencing resilience in anorexia nervosa (AN) patients. Twenty female patients with AN (median age =30.0 years, quartile deviation =6.8) and 40 female healthy controls (HCs) (median age =30.0 years, quartile deviation =8.6) participated in the present study. Resilience was assessed with the Connor- Davidson resilience scale (CD-RISC). Clinical symptoms were evaluated with the structured interview guide for the Hamilton depression rating scale (SIGH-D) and the eating disorder inventory-2 (EDI-2). Scores of the CD-RISC in the AN group were lower than those in the HC group, and the SIGH-D score in the AN group was higher than that in the HC group. Scores of interoceptive confusion, interpersonal difficulty and negative self-image subscales of the EDI-2 negatively correlated with the CD-RISC score. Moreover, stepwise regression analysis showed that negative self-image score was an independent predictor of the CD-RISC score. These results suggest that among these clinical factors including psychopathologies, self-dissatisfaction and feeling of being rejected by others are the most important influencing factors on an AN patients' resilience. (Tokushima University Institutional Repository) ● Metadata: 115649 (Link to Publication Site) ● Publication site (DOI): 10.2147/NDT.S190725 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30787613 ● Summary page in Scopus @ Elsevier: 2-s2.0-85062653550 (Tokushima University Institutional Repository: 115649, DOI: 10.2147/NDT.S190725, PubMed: 30787613, Elsevier: Scopus)
16.	Tomoya Takeda, Masahito Nakataki, Masashi Ohta, S Hamatani, K Matsuura, R Yoshida, Naomi Kameoka, Takeo Tominaga, Hidehiro Umehara, Makoto Kinoshita, Shinya Watanabe, Shusuke Numata, Satsuki Sumitani and Tetsuro Ohmori : Negative and positive self-thoughts predict subjective quality of life in people with schizophrenia., Neuropsychiatric Disease and Treatment, Vol.15, 293-301, 2019. (Summary) Recently, cognitive variables such as negative and positive self-belief and thoughts have attracted much attention because they are associated with functional outcomes and quality of life (QOL). However, it is unclear how cognitive variables affect subjective and objective QOL. This study aimed to investigate the relationship of negative and positive self-belief and thoughts with subjective and objective QOL. Thirty-six people with schizophrenia participated in this study. Subjective and objective QOL were assessed with the Schizophrenia Quality of Life Scale (SQLS) and Quality of Life Scale (QLS), respectively. Neurocognitive function was assessed with the Brief Assessment of Cognition in Schizophrenia (BACS). Clinical symptoms were assessed with the Positive and Negative Syndrome Scale and Calgary Depression Scale for Schizophrenia. Side effects were assessed with the Drug-induced Extrapyramidal Symptoms Scale (DIEPSS). Negative and positive self-belief and thoughts were assessed with the Defeatist Performance Belief Scale and Automatic Thoughts Questionnaire-Revised. A generalized linear model was tested, with subjective and objective QOL as the response variable and symptoms, neurocognitive function, and cognitive variables that were significantly correlated with subjective and objective QOL as explanatory variables. In the schizophrenia group, the common objects score on the QLS was predicted by the composite BACS score, and the total QLS score was predicted by the DIEPSS score. Motivation and Energy, Psychosocial, and Symptoms and Side effects scores on the SQLS were predicted by depression and by negative automatic thought (NAT) and positive automatic thought (PAT). Our results indicated that key targets for improving objective and subjective QOL in people with schizophrenia are side effects, neurocognitive function, depression, and NAT and PAT. (Tokushima University Institutional Repository) ● Metadata: 113356 (Link to Publication Site) ● Publication site (DOI): 10.2147/NDT.S190381 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30718955 ● Summary page in Scopus @ Elsevier: 2-s2.0-85062679097 (Tokushima University Institutional Repository: 113356, DOI: 10.2147/NDT.S190381, PubMed: 30718955, Elsevier: Scopus)
17.	Makoto Kinoshita, Masahito Nakataki, Ryoma Morigaki, Satsuki Sumitani, Satoshi Goto, Ryuji Kaji and Tetsuro Ohmori : Turning on the Left Side Electrode Changed Depressive State to Manic State in a Parkinson's Disease Patient Who Received Bilateral Subthalamic Nucleus Deep Brain Stimulation: A Case Report., Clinical Psychopharmacology and Neuroscience, Vol.16, No.4, 494-496, 2018. (Summary) No previous reports have described a case in which deep brain stimulation elicited an acute mood swing from a depressive to manic state simply by switching one side of the bilateral deep brain stimulation electrode on and off. The patient was a 68-year-old woman with a 10-year history of Parkinson's disease. She underwent bilateral subthalamic deep brain stimulation surgery. After undergoing surgery, the patient exhibited hyperthymia. She was scheduled for admission. On the first day of admission, it was clear that resting tremors in the right limbs had relapsed and her hyperthymia had reverted to depression. It was discovered that the left-side electrode of the deep brain stimulation device was found to be accidentally turned off. As soon as the electrode was turned on, motor impairment improved and her mood switched from depression to mania. The authors speculate that the lateral balance of stimulation plays an important role in mood regulation. The current report provides an intriguing insight into possible mechanisms of mood swing in mood disorders. (Tokushima University Institutional Repository) ● Metadata: 114301 (Link to Publication Site) ● Publication site (DOI): 10.9758/cpn.2018.16.4.494 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30466222 ● Summary page in Scopus @ Elsevier: 2-s2.0-85055838752 (Tokushima University Institutional Repository: 114301, DOI: 10.9758/cpn.2018.16.4.494, PubMed: 30466222, Elsevier: Scopus)
18.	Takeo Tominaga, Masahito Tomotake, Tomoya Takeda, Yoshinori Ueoka, Tsunehiko Tanaka, Shinya Watanabe, Naomi Kameoka, Masahito Nakataki, Shusuke Numata, Yumiko Izaki, Satsuki Sumitani, hiroko Kubo, Yasuhiro Kaneda and Tetsuro Ohmori : Relationship between social and cognitive functions in people with schizophrenia, Neuropsychiatric Disease and Treatment, Vol.14, 2215-2224, 2018. (Summary) The purpose of the present study was to examine clinical factors related to social function in people with schizophrenia. The participants were 55 stabilized outpatients with schizophrenia. Their mean age was 39.36 (SD =10.65) years. Social function was assessed using the Quality of Life Scale (QLS). Cognitive function was evaluated with the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB). Clinical symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS), the Calgary Depression Scale for Schizophrenia, and the Drug-Induced Extrapyramidal Symptoms Scale. Neither the MCCB cognitive domain score nor composite score was correlated with the QLS scores. However, of the 10 MCCB subtests, the Trail Making Test Part A and the Brief Assessment of Cognition in Schizophrenia-Symbol Coding (BACS-SC) scores were positively correlated with the QLS scores. Among clinical variables, especially the PANSS negative syndrome scale score had a strong negative correlation with the QLS scores. Stepwise regression analyses showed that the PANSS negative syndrome scale score was an independent predictor of the QLS scores, and although the BACS-SC score predicted the QLS common objects and activities subscale score, the association was not so strong compared to the PANSS negative syndrome scale score. These results indicate that speed of processing evaluated by BACS-SC could predict some aspect of social function but negative symptoms have a much stronger impact on global social function in people with schizophrenia. (Tokushima University Institutional Repository) ● Metadata: 114525 (Link to Publication Site) ● Publication site (DOI): 10.2147/NDT.S171207 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30214211 ● Summary page in Scopus @ Elsevier: 2-s2.0-85057540520 (Tokushima University Institutional Repository: 114525, DOI: 10.2147/NDT.S171207, PubMed: 30214211, Elsevier: Scopus)
19.	LM Soravia, S Schwab, N Weber, Masahito Nakataki, R Wiest, W Strik, M Heinrichs, D Quervain de and A. Federspiel : Glucocorticoid administration restores salience network activity in patients with spider phobia., Depression and Anxiety, Vol.35, No.10, 925-934, 2018. (Summary) Glucocorticoids reduce phobic fear in patients with anxiety disorders. Although the neurobiology of anxiety disorders is not fully understood, convergent structural and functional neuroimaging studies have identified abnormalities in various brain regions, including those in the salience network (SN) and default mode network (DMN). Here, we examine the effects of glucocorticoid administration on SN and DMN activity during the processing of phobic stimuli. We use functional magnetic resonance imaging to record brain activity in 24 female patients with spider phobia who were administered either 20 mg of cortisol or placebo while viewing pictures of spiders. Fourteen healthy female participants were tested with the same task but without substance administration. Independent component analysis (ICA) performed during stimulus encoding identified the SN and DMN as exhibiting synchronized activation in diverse brain regions; thus, we examined the effects of cortisol on these networks. Furthermore, participants had to rate their level of fear at various time points. Glucocorticoids reduced phobic fear in patients with spider phobia. The ICA performed during stimulus encoding revealed that activity in the SN and DMN was reduced in placebo-treated patients versus healthy controls. Brain activity in the SN, but not the DMN, was altered in cortisol- versus placebo-treated patients to a level that was similar to that observed in healthy controls. Activity in both the SN and DMN was reduced in patients with spider phobia. Cortisol administration altered the SN activity to a level that was comparable to that found in healthy controls. This alteration in SN activity might reflect the fear-reducing effects of glucocorticoids in phobia. (Keyword) Adolescent / Adult / Animals / Brain / Case-Control Studies / Double-Blind Method / Fear / Female / Functional Neuroimaging / Glucocorticoids / Humans / Hydrocortisone / Magnetic Resonance Imaging / Male / Neural Pathways / Phobic Disorders / Spiders / Young Adult (Link to Publication Site) ● Publication site (DOI): 10.1002/da.22806 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 30099829 ● Summary page in Scopus @ Elsevier: 2-s2.0-85052491471 (DOI: 10.1002/da.22806, PubMed: 30099829, Elsevier: Scopus)
20.	Masashi Ohta, Masahito Nakataki, Tomoya Takeda, Shusuke Numata, Takeo Tominaga, Naomi Kameoka, Hiroko Kubo, Makoto Kinoshita, K Matsuura, M Otomo, N Takeichi, Masafumi Harada and Tetsuro Ohmori : Structural equation modeling approach between salience network dysfunction, depressed mood, and subjective quality of life in schizophrenia: an ICA resting-state fMRI study., Neuropsychiatric Disease and Treatment, Vol.14, 1585-1597, 2018. (Summary) Quality of life (QOL) is an important clinical outcome for patients with schizophrenia, and recent studies have focused on subjective QOL. We evaluated the causal relationship between psychosocial aspect of subjective QOL, symptoms, cognitive functions, and salience network (SN) dysfunction in schizophrenia using structural equation modeling (SEM). We performed a cross-sectional study of 21 patients with symptomatically stabilized schizophrenia and 21 age-, sex-, and education level-matched healthy controls who underwent resting-state functional magnetic resonance imaging. We evaluated SN dysfunction in schizophrenia using independent component analysis (ICA). We rated participant psychopathology using the Positive and Negative Syndrome Scale (PANSS), the Brief Assessment of Cognition in Schizophrenia (BACS), and the Calgary Depression Scale for Schizophrenia (CDSS). We rated psychosocial aspect of subjective QOL using the Schizophrenia Quality of Life Scale (SQLS) psychosocial subscale. We applied SEM to examine the relationships between SN dysfunction, PANSS positive and negative scores, CDSS total scores, BACS composite scores, and SQLS psychosocial subscale scores. In second-level analysis after group ICA, patient group had significant lower right pallidum functional connectivity (FC) within the SN than the controls did (Montreal Neurological Institute [MNI] [] = [22 -2 -6]) ( = 0.027, family-wise error [FWE] corrected). In SEM, we obtained a good fit for an SEM model in which SN dysfunction causes depressed mood, which in turn determines psychosocial aspect of subjective QOL (chi-squared = 0.9, root mean square error of approximation (RMSEA) < 0.001, comparative fit index [CFI] = 1.00, and standardized root mean square residual [SRMR]= 0.020). We found a continuous process by which SN dysfunction causes depressed moods that determine psychosocial aspect of subjective QOL in schizophrenia. This is the first report that offers a unified explanation of functional neuroimaging, symptoms, and outcomes. Future studies combining neuroimaging techniques and clinical assessments would elucidate schizophrenia's pathogenesis. (Tokushima University Institutional Repository) ● Metadata: 113339 (Link to Publication Site) ● Publication site (DOI): 10.2147/NDT.S163132 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29942132 ● Summary page in Scopus @ Elsevier: 2-s2.0-85048683537 (Tokushima University Institutional Repository: 113339, DOI: 10.2147/NDT.S163132, PubMed: 29942132, Elsevier: Scopus)
21.	Tomoya Takeda, Masahito Nakataki, Masashi Ohta, Sayo Hamatani, Kanae Matsuura and Tetsuro Ohmori : Effect of cognitive function on jumping to conclusion in patients with schizophrenia., Schizophrenia Research. Cognition, Vol.12, 50-55, 2018. (Summary) The "jumping to conclusion" (JTC) bias is related to the formation and maintenance of delusions. Higher JTC bias can be based on both neurocognitive dysfunction and social cognitive dysfunction in patients with schizophrenia. The aim of this study was to assess the relationship between JTC bias, neurocognition, and social cognition in patients with schizophrenia. A total of 22 patients with schizophrenia and 21 controls participated in this study. Neurocognition and social cognition were assessed using the Brief Assessment of Cognition in Schizophrenia (BACS) and Social Cognition Screening Questionnaire (SCSQ), respectively. The JTC bias and the decision confidence were assessed using the beads task. The patients were classified into the JTC group (with higher JTC bias; n = 10) and JTC-non group (n = 12). The JTC group scored significantly lower on verbal memory, working memory, and motor speed sub-scores of BACS than the JTC-non group. No difference in social cognition was observed between the two groups. The decision confidence was predicted by metacognition, which is an SCSQ sub-score. Similarly to the patients, the controls were classified into the JTC group (higher JTC bias; n = 9) and the JTC-non group (n = 12). There were no significant differences in neurocognition and social cognition between the control JTC and JTC-non groups. The present results indicated that JTC bias is related to neurocognition and decision confidence is related to social cognition in patients with schizophrenia. These findings may bridge the gaps between psychotic symptom and cognitive dysfunction in schizophrenia. (Tokushima University Institutional Repository) ● Metadata: 115715 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.scog.2018.04.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29928597 ● Summary page in Scopus @ Elsevier: 2-s2.0-85046754835 (Tokushima University Institutional Repository: 115715, DOI: 10.1016/j.scog.2018.04.002, PubMed: 29928597, Elsevier: Scopus)
22.	Yukiko Tomioka, Shusuke Numata, Makoto Kinoshita, Hidehiro Umehara, Shinya Watanabe, Masahito Nakataki, Y Iwayama, T Toyota, M Ikeda, H Yamamori, S Shimodera, A Tajima, R Hashimoto, N Iwata, T Yoshikawa and Tetsuro Ohmori : Decreased serum pyridoxal levels in schizophrenia: meta-analysis and Mendelian randomization analysis., Journal of Psychiatry & Neuroscience, Vol.43, No.3, 194-200, 2018. (Summary) Alterations in one-carbon metabolism have been associated with schizophrenia, and vitamin B6 is one of the key components in this pathway. We first conducted a case-control study of serum pyridoxal levels and schizophrenia in a large Japanese cohort ( = 1276). Subsequently, we conducted a meta-analysis of association studies ( = 2125). Second, we investigated whether rs4654748, which was identified in a genome-wide association study as a vitamin B6-related single nucleotide polymorphism, was genetically implicated in patients with schizophrenia in the Japanese population ( = 10 689). Finally, we assessed the effect of serum pyridoxal levels on schizophrenia risk using a Mendelian randomization (MR) approach. Serum pyridoxal levels were significantly lower in patients with schizophrenia than in controls, not only in our cohort, but also in the pooled data set of the meta-analysis of association studies (standardized mean difference -0.48, 95% confidence interval [CI] -0.57 to -0.39, = 9.8 × 10-24). We failed to find a significant association between rs4654748 and schizophrenia. Furthermore, an MR analysis failed to find a causal relationship between pyridoxal levels and schizophrenia risk (odds ratio 0.99, 95% CI 0.65-1.51, = 0.96). Food consumption and medications may have affected serum pyridoxal levels in our cross-sectional study. Sample size, number of instrumental variables and substantial heterogeneity among patients with schizophrenia are limitations of an MR analysis. We found decreased serum pyridoxal levels in patients with schizophrenia in this observational study. However, we failed to obtain data supporting a causal relationship between pyridoxal levels and schizophrenia risk using the MR approach. (Tokushima University Institutional Repository) ● Metadata: 114064 (Link to Publication Site) ● Publication site (DOI): 10.1503/jpn.170053 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29688875 ● Search Scopus @ Elsevier (PMID): 29688875 ● Search Scopus @ Elsevier (DOI): 10.1503/jpn.170053 (Tokushima University Institutional Repository: 114064, DOI: 10.1503/jpn.170053, PubMed: 29688875)
23.	Masatoshi Inoshita, Hidehiro Umehara, Shinya Watanabe, Masahito Nakataki, Makoto Kinoshita, Yukiko Tomioka, Atsushi Tajima, Shusuke Numata and Tetsuro Ohmori : Elevated peripheral blood glutamate levels in major depressive disorder., Neuropsychiatric Disease and Treatment, Vol.14, 945-953, 2018. (Summary) There is growing evidence that glutamatergic signaling may be involved in major depressive disorder (MDD). In regard to peripheral blood glutamate changes in MDD, inconsistent findings have been reported. The purpose of the present study was to evaluate whether blood glutamate levels differed between MDD patients and control participants. We conducted a systematic review and meta-analysis of 12 association studies between blood glutamate levels and MDD in a total of 529 MDD patients and 590 controls. Subsequently, we conducted subgroup analyses and a meta-regression analysis to examine the sources of potential heterogeneity. A random effects model showed that blood glutamate levels were significantly higher in MDD patients than in controls (standardized mean difference=0.54, 95% CI=0.27-0.82, =8.5×10) with high heterogeneity (=75.0%, <0.05). Subgroup analyses showed elevated glutamate levels in MDD patients compared with controls in plasma, but not serum studies, and in studies using high-performance liquid chromatography but not with mass spectrometry for glutamate assay. A meta-regression analysis showed no effects of age, gender, medication use, sample size, and published year on blood glutamate levels. Our findings suggest that altered glutamate levels may be implicated in MDD, which provides further evidence of glutamatergic dysfunction in MDD. (Tokushima University Institutional Repository) ● Metadata: 114063 (Link to Publication Site) ● Publication site (DOI): 10.2147/NDT.S159855 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29670355 ● Summary page in Scopus @ Elsevier: 2-s2.0-85045521393 (Tokushima University Institutional Repository: 114063, DOI: 10.2147/NDT.S159855, PubMed: 29670355, Elsevier: Scopus)
24.	Hideo Mure, Ryoma Morigaki, Ryosuke Miyamoto, Masahito Nakataki, 岡久哲也, Shinsuke Katoh, Ryuji Kaji, Yasushi Takagi, Shinji Nagahiro and Satoshi Goto : Multi-disciplinary approach for dystonia patients by treatment with deep brain stimulation, Functional Neurosurgery, Vol.57, 35-39, 2018. (Keyword) ジストニア / 脳深部刺激療法 / 多職種連携 / Dystonia / DBS / Multidisciplinary / Collaboration (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520572358412476800 (CiNii: 1520572358412476800)
25.	Kristoffer Daniel Fehér, Masahito Nakataki and Yosuke Morishima : Phase-Dependent Modulation of Signal Transmission in Cortical Networks through tACS-Induced Neural Oscillations., Frontiers in Human Neuroscience, Vol.11, 471, 2017. (Summary) Oscillatory neural activity is considered a basis of signal transmission in brain networks. However, the causal role of neural oscillations in regulating cortico-cortical signal transmission has so far not been directly demonstrated. To date, due to methodological limitations, studies on the online modulatory mechanisms of transcranial alternating current stimulation (tACS)-induced neural oscillations are confined to the primary motor cortex. To address the causal role of oscillatory activity in modulating cortico-cortical signal transmission, we have established a new method using concurrent tACS, transcranial magnetic stimulation (TMS) and electroencephalography (EEG). Through tACS, we introduced 6-Hz (theta) oscillatory activity in the human dorsolateral prefrontal cortex (DLPFC). During tACS, we applied single-pulse TMS over the DLPFC at different phases of tACS and assessed propagation of TMS-induced neural activity with EEG. We show that tACS-induced theta oscillations modulate the propagation of TMS-induced activity in a phase-dependent manner and that phase-dependent modulation is not simply explained by the instantaneous amplitude of tACS. The results demonstrate a phase-dependent modulatory mechanism of tACS at a cortical network level, which is consistent with a causal role of neural oscillations in regulating the efficacy of signal transmission in the brain. (Tokushima University Institutional Repository) ● Metadata: 114491 (Link to Publication Site) ● Publication site (DOI): 10.3389/fnhum.2017.00471 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 29021749 ● Summary page in Scopus @ Elsevier: 2-s2.0-85032030008 (Tokushima University Institutional Repository: 114491, DOI: 10.3389/fnhum.2017.00471, PubMed: 29021749, Elsevier: Scopus)
26.	Kazuo Takiguchi, Akihito Uezato, Michio Itasaka, Hidenori Atsuta, Kenji Narushima, Naoki Yamamoto, Akeo Kurumaji, Makoto Tomita, Kazunari Oshima, Kosaku Shoda, Mai Tamaru, Masahito Nakataki, Mitsutoshi Okazaki, Sayuri Ishiwata, Yasuyoshi Ishiwata, Masato Yasuhara, Kunimasa Arima, Tetsuro Ohmori and Toru Nishikawa : Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study., BMC Psychiatry, Vol.17, No.1, 249, 2017. (Summary) It has been reported that drugs which promote the N-Methyl-D-aspartate-type glutamate receptor function by stimulating the glycine modulatory site in the receptor improve negative symptoms and cognitive dysfunction in schizophrenia patients being treated with antipsychotic drugs. We performed a placebo-controlled double-blind crossover study involving 41 schizophrenia patients in which D-cycloserine 50 mg/day was added-on, and the influence of the onset age and association with white matter integrity on MR diffusion tensor imaging were investigated for the first time. The patients were evaluated using the Positive and Negative Syndrome Scale (PANSS), Scale for the Assessment of Negative Symptoms (SANS), Brief Assessment of Cognition in Schizophrenia (BACS), and other scales. D-cycloserine did not improve positive or negative symptoms or cognitive dysfunction in schizophrenia. The investigation in consideration of the onset age suggests that D-cycloserine may aggravate negative symptoms of early-onset schizophrenia. The better treatment effect of D-cycloserine on BACS was observed when the white matter integrity of the sagittal stratum/ cingulum/fornix stria terminalis/genu of corpus callosum/external capsule was higher, and the better treatment effect on PANSS general psychopathology (PANSS-G) was observed when the white matter integrity of the splenium of corpus callosum was higher. In contrast, the better treatment effect of D-cycloserine on PANSS-G and SANS-IV were observed when the white matter integrity of the posterior thalamic radiation (left) was lower. It was suggested that response to D-cycloserine is influenced by the onset age and white matter integrity. UMIN Clinical Trials Registry (number UMIN000000468 ). Registered 18 August 2006. (Keyword) Adult / Age of Onset / Antipsychotic Agents / Cross-Over Studies / Cycloserine / Diffusion Tensor Imaging / Double-Blind Method / Drug Therapy, Combination / Female / Glycine Agents / Humans / Male / Middle Aged / schizophrenia / Schizophrenic Psychology / White Matter (Tokushima University Institutional Repository) ● Metadata: 114062 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12888-017-1410-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 28701225 ● Summary page in Scopus @ Elsevier: 2-s2.0-85023199149 (Tokushima University Institutional Repository: 114062, DOI: 10.1186/s12888-017-1410-3, PubMed: 28701225, Elsevier: Scopus)
27.	Hiroko Kubo, Masahito Nakataki, Satsuki Sumitani, Junichi Iga, Shusuke Numata, Naomi Kameoka, Shinya Watanabe, Hidehiro Umehara, Makoto Kinoshita, Masatoshi Inoshita, Mai Tamaru, Masashi Ohta, Chiaki Nakayama-Yamauchi, Yasuhiro Funakoshi, Masafumi Harada and Tetsuro Ohmori : 1H-magnetic resonance spectroscopy study of glutamate-related abnormality in bipolar disorder., Journal of Affective Disorders, Vol.208, 139-144, 2017. (Summary) Previous studies of patients with bipolar disorder (BD) using magnetic resonance spectroscopy (MRS) have shown neurophysiological abnormalities related to the glutamate (Glu)-glutamine (Gln) cycle, membrane turnover, and neuronal integrity, although the results were neither consistent nor conclusive. Recently it has been reported the Gln/Glu ratio is the most useful index, quantifying neuronal-glial interactions and the balance of glutamatergic metabolites In this MRS study, we elucidated the abnormalities of metabolites in a larger sample of patients with BD with a high-field MRI system. Sixty-two subjects (31 patients with BD and 31 healthy controls [HC]) underwent 3T proton MRS (1H-MRS) of the anterior cingulate cortex (ACC) and left basal ganglia (ltBG) using a stimulated echo acquisition mode (STEAM) sequence. After verifying the data quality, 20 patients with BD and 23 age- and gender-matched HCs were compared using repeated-measures analysis of covariance (ANCOVA). Compared to the HC group, the BD group showed increased levels of Gln, creatine (Cr), N-acetyl aspartate (NAA), choline (Cho), and an increased ratio of Gln to Glu in the ACC, and increased Gln and Cho in the ltBG. These findings remained after the participants with BD were limited to only euthymic patients. After removing the influence of lithium (Li) and sodium valproate (VPA), we observed activated glutamatergic neurotransmission in the ACC but not in the ltBG. The present findings are cross-sectional and metabolites were measured in only two regions. Our results support a wide range of metabolite changes in patients with BD involved in glutamatergic neurotransmission, membrane turnover, and neuronal integrity. Moreover, the elevation of Gln/Glu ratio suggested that hyperactivity of glutamatergic neurotransmission in the ACC is a disease marker for BD. (Tokushima University Institutional Repository) ● Metadata: 109987 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jad.2016.08.046 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27770643 ● Summary page in Scopus @ Elsevier: 2-s2.0-85008670828 (Tokushima University Institutional Repository: 109987, DOI: 10.1016/j.jad.2016.08.046, PubMed: 27770643, Elsevier: Scopus)
28.	Masahito Nakataki, Leila M Soravia, Simon Schwab, Helge Horn, Thomas Dierks, Werner Strik, Roland Wiest, Markus Heinrichs, Dominique de J-F Quervain, Andrea Federspiel and Yosuke Morishima : Glucocorticoid Administration Improves Aberrant Fear-Processing Networks in Spider Phobia., Neuropsychopharmacology, Vol.42, No.2, 485-494, 2017. (Summary) Glucocorticoids reduce phobic fear in patients with anxiety disorders. Previous studies have shown that fear-related activation of the amygdala can be mediated through the visual cortical pathway, which includes the fusiform gyrus, or through other pathways. However, it is not clear which of the pathways that activate the amygdala is responsible for the pathophysiology of a specific phobia and how glucocorticoid treatment alleviates fear processing in these neural networks. We recorded the brain activity with functional magnetic resonance imaging in patients with spider phobia, who received either 20 mg of cortisol or a placebo while viewing pictures of spiders. We also tested healthy participants who did not receive any medication during the same task. We performed dynamic causal modelling (DCM), a connectivity analysis, to examine the effects of cortisol on the networks involved in processing fear and to examine if there was an association between these networks and the symptoms of the phobia. Cortisol administration suppressed the phobic stimuli-related amygdala activity to levels comparable to the healthy participants and reduced subjective phobic fear. The DCM analysis revealed that cortisol administration suppressed the aberrant inputs into the amygdala that did not originate from the visual cortical pathway, but rather from a fast subcortical pathway mediated by the pulvinar nucleus, and suppressed the interactions between the amygdala and fusiform gyrus. This network changes were distinguishable from healthy participants and considered the residual changes under cortisol administration. We also found that the strengths of the aberrant inputs into the amygdala were positively correlated with the severity of spider phobia. This study demonstrates that patients with spider phobia show an aberrant functional connectivity of the amygdala when they are exposed to phobia-related stimuli and that cortisol administration can alleviate this fear-specific neural connectivity. (Keyword) Adult / Amygdala / Animals / brain / Brain Mapping / Fear / Female / Glucocorticoids / Humans / Hydrocortisone / magnetic resonance imaging / Male / Neural Pathways / Phobic Disorders / Spiders / Visual Cortex / Young Adult (Link to Publication Site) ● Publication site (DOI): 10.1038/npp.2016.207 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27644128 ● Summary page in Scopus @ Elsevier: 2-s2.0-84991037558 (DOI: 10.1038/npp.2016.207, PubMed: 27644128, Elsevier: Scopus)
29.	LM Soravia, A Orosz, S Schwab, Masahito Nakataki, R Wiest and A Federspiel : CBT reduces CBF: cognitive-behavioral therapy reduces cerebral blood flow in fear-relevant brain regions in spider phobia., Brain and Behavior, Vol.6, No.9, e00510, 2016. (Summary) Imaging studies have provided evidence that cognitive-behavioral therapy (CBT) is able to change brain activation in phobic patients in response to threatening stimuli. The changes occurred in both emotion-generating and modulatory regions. In this study, we use a data-driven approach to explore resting state cerebral blood flow (CBF) measured by arterial spin labeling (ASL), before and after CBT. Eight female patients with spider phobia were scanned before and 1 month after an exposure-based group therapy for spider phobia. Each MRI session consisted of an ASL resting state measurement acquired before and after a symptom provocation task involving the showing of spider pictures in the scanner. The first ASL acquisition measured anticipatory anxiety and the second measured postprocessing of phobia-relevant stimuli. Cognitive-behavioral therapy significantly reduced spider phobic symptoms in all patients. Symptom reduction during anticipatory anxiety was accompanied by reduced bilateral CBF in the parahippocampal gyrus, ventral anterior thalamus, Brodmann area 8, and the anterior cingulate cortex. During postprocessing of phobia-relevant stimuli, patients showed reduced CBF in the bilateral insula, components of the motor cortex, and areas associated with language functions. Longitudinal CBF dynamics following CBT were in concordance with results from several studies using BOLD fMRI to investigate the effects of psychotherapy on brain activity. CBF can be quantified by ASL, with the principal advantage of sensitivity to slow variations in neural activity and task independence. Therefore, ASL may be a suitable method for monitoring and evaluating the efficacy of psychotherapy or pharmacotherapy approaches. (Tokushima University Institutional Repository) ● Metadata: 115030 (Link to Publication Site) ● Publication site (DOI): 10.1002/brb3.510 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27688940 ● Search Scopus @ Elsevier (PMID): 27688940 ● Search Scopus @ Elsevier (DOI): 10.1002/brb3.510 (Tokushima University Institutional Repository: 115030, DOI: 10.1002/brb3.510, PubMed: 27688940)
30.	Hidehiro Umehara, Shusuke Numata, Atsushi Tajima, Akira Nishi, Masahito Nakataki, Issei Imoto, Satsuki Sumitani and Tetsuro Ohmori : Calcium Signaling Pathway Is Associated with the Long-Term Clinical Response to Selective Serotonin Reuptake Inhibitors (SSRI) and SSRI with Antipsychotics in Patients with Obsessive-Compulsive Disorder., PLoS ONE, Vol.11, No.6, e0157232., 2016. (Summary) Selective serotonin reuptake inhibitors (SSRI) are established first-line pharmacological treatments for obsessive-compulsive disorder (OCD), while antipsychotics are used as an augmentation strategy for SSRI in OCD patients who have either no response or a partial response to SSRI treatment. The goal of the present study was to identify genetic variants and pathways that are associated with the long-term clinical response of OCD patients to SSRI or SSRI with antipsychotics. We first performed a genome-wide association study of 96 OCD patients to examine genetic variants contributing to the response to SSRI or SSRI with antipsychotics. Subsequently, we conducted pathway-based analyses by using Improved Gene Set Enrichment Analysis for Genome-wide Association Study (i-GSEA4GWAS) to examine the combined effects of genetic variants on the clinical response in OCD. While we failed to detect specific genetic variants associated with clinical responses to SSRI or to SSRI with an atypical antipsychotic at genome-wide levels of significance, we identified 8 enriched pathways for the SSRI treatment response and 5 enriched pathways for the treatment response to SSRI with an antipsychotic medication. Notably, the calcium signaling pathway was identified in both treatment responses. Our results provide novel insight into the molecular mechanisms underlying the variability in clinical response to SSRI and SSRI with antipsychotics in OCD patients. (Tokushima University Institutional Repository) ● Metadata: 110039 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0157232 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 27281126 ● Summary page in Scopus @ Elsevier: 2-s2.0-84975507364 (Tokushima University Institutional Repository: 110039, DOI: 10.1371/journal.pone.0157232, PubMed: 27281126, Elsevier: Scopus)
31.	LM Soravia, JS Witmer, S Schwab, Masahito Nakataki, T Dierks, R Wiest, K Henke, A Federspiel and K Jann : Prestimulus default mode activity influences depth of processing and recognition in an emotional memory task., Human Brain Mapping, Vol.37, No.3, 924-932, 2016. (Summary) Low self-referential thoughts are associated with better concentration, which leads to deeper encoding and increases learning and subsequent retrieval. There is evidence that being engaged in externally rather than internally focused tasks is related to low neural activity in the default mode network (DMN) promoting open mind and the deep elaboration of new information. Thus, reduced DMN activity should lead to enhanced concentration, comprehensive stimulus evaluation including emotional categorization, deeper stimulus processing, and better long-term retention over one whole week. In this fMRI study, we investigated brain activation preceding and during incidental encoding of emotional pictures and on subsequent recognition performance. During fMRI, 24 subjects were exposed to 80 pictures of different emotional valence and subsequently asked to complete an online recognition task one week later. Results indicate that neural activity within the medial temporal lobes during encoding predicts subsequent memory performance. Moreover, a low activity of the default mode network preceding incidental encoding leads to slightly better recognition performance independent of the emotional perception of a picture. The findings indicate that the suppression of internally-oriented thoughts leads to a more comprehensive and thorough evaluation of a stimulus and its emotional valence. Reduced activation of the DMN prior to stimulus onset is associated with deeper encoding and enhanced consolidation and retrieval performance even one week later. Even small prestimulus lapses of attention influence consolidation and subsequent recognition performance. (Keyword) Adult / Brain / Brain Mapping / Emotions / Female / Humans / Magnetic Resonance Imaging / Male / Middle Aged / Neuropsychological Tests / Pattern Recognition, Visual / Photic Stimulation / Recognition (Psychology) / Time / Young Adult (Link to Publication Site) ● Publication site (DOI): 10.1002/hbm.23076 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 26663662 ● Search Scopus @ Elsevier (PMID): 26663662 ● Search Scopus @ Elsevier (DOI): 10.1002/hbm.23076 (DOI: 10.1002/hbm.23076, PubMed: 26663662)
32.	Shinya Watanabe, Junichi Iga, Akira Nishi, Shusuke Numata, Makoto Kinoshita, K Kikuchi, Masahito Nakataki and Tetsuro Ohmori : Microarray analysis of global gene expression in leukocytes following lithium treatment., Human Psychopharmacology, Vol.29, No.2, 190-198, 2014. (Summary) To elucidate the molecular effects of lithium, we studied global gene expression changes induced by lithium in leukocytes from healthy subjects. Eight healthy male subjects participated in this study. Lithium was prescribed for weeks to reach a therapeutic serum concentration. Leukocyte counts and serum lithium concentrations were determined at baseline (before medication), after 1 and 2 weeks of medication and at 2 weeks after stopping medication. Gene expression profiling was performed at each time point using Agilent G4112F Whole Human Genome arrays (The Agilent Technologies, Santa Clara, CA, USA). Expression of some candidate genes was also assessed by real-time polymerase chain reaction (PCR). Gene ontology analysis revealed that the cellular and immune responses to stimulus and stress indeed played a major role in the cellular response to lithium treatment. Pathway analysis revealed that the interleukin 6 pathway, the inhibitor of differentiation pathway, and the methane metabolism pathway were regulated by lithium. Using real-time PCR, we also confirmed that five candidate genes in these pathways were significantly changed, including suppressor of cytokine signaling 3 and myeloperoxidase. Our investigation suggests that the molecular action of lithium is mediated in part by its effects on the cellular and immune response to stimulus and stress followed by the interleukin 6, inhibitor of differentiation, and methane metabolism pathways. (Keyword) Antimanic Agents / Gene Expression / Gene Expression Profiling / Humans / Interleukin-6 / Leukocyte Count / Leukocytes / Lithium Compounds / Male / Methane / Microarray Analysis / Peroxidase / Polymerase Chain Reaction / Signal Transduction / Suppressor of Cytokine Signaling Proteins / Time Factors (Tokushima University Institutional Repository) ● Metadata: 106183 (Link to Publication Site) ● Publication site (DOI): 10.1002/hup.2381 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 24590544 ● Summary page in Scopus @ Elsevier: 2-s2.0-84895525304 (Tokushima University Institutional Repository: 106183, DOI: 10.1002/hup.2381, PubMed: 24590544, Elsevier: Scopus)
33.	Makoto Kinoshita, Shusuke Numata, Atsushi Tajima, S Shimodera, S Ono, A Imamura, Junichi Iga, Shinya Watanabe, Kumiko Kikuchi, Hiroko Kubo, Masahito Nakataki, Satsuki Sumitani, Issei Imoto, Y Okazaki and Tetsuro Ohmori : DNA Methylation Signatures of Peripheral Leukocytes in Schizophrenia., NeuroMolecular Medicine, Vol.Mar;15, No.1, 95-101, 2013. (Summary) Schizophrenia (SCZ) is a complex psychiatric disease with a lifetime morbidity rate of 0.5-1.0 %. To date, aberrant DNA methylation in SCZ has been reported in several studies. However, no comprehensive studies using medication-free subjects with SCZ have been conducted. In addition, most of these studies have been limited to the analysis of the CpG sites in CpG islands (CGIs) in the gene promoter regions, so little is known about the DNA methylation signatures across the whole genome in SCZ. Genome-wide DNA methylation profiling (485,764 CpG sites) of peripheral leukocytes was conducted in the first set of samples (24 medication-free patients with SCZ and 23 non-psychiatric controls) using Infinium HumanMethylation450 Beadchips. Second, a monozygotic twin study was performed using three pairs of monozygotic twins that were discordant for SCZ. Finally, the data from these two independent cohorts were compared. A total of 234 differentially methylated CpG sites that were common between these two cohorts were identified. Of the 234 CpG sites, 153 sites (65.4 %) were located in the CGIs and in the regions flanking CGIs (CGI: 40.6 %; CGI shore: 13.3 %; CGI shelf: 11.5 %). Of the 95 differently methylated CpG sites in the CGIs, most of them were located in the promoter regions (promoter: 75.8 %; gene body: 14.7 %; 3'-UTR: 2.1 %). Aberrant DNA methylation in SCZ was identified at numerous loci across the whole genome in peripheral leukocytes using two independent sets of samples. These findings support the notion that altered DNA methylation could be involved in the pathophysiology of SCZ. (Keyword) 3' Untranslated Regions / Adult / Antipsychotic Agents / Cohort Studies / CpG Islands / DNA Methylation / DNA, Intergenic / Diseases in Twins / Female / Humans / Japan / Leukocytes / Male / Promoter Regions, Genetic / Schizophrenia / Twins, Monozygotic / Young Adult (Tokushima University Institutional Repository) ● Metadata: 106144 (Link to Publication Site) ● Publication site (DOI): 10.1007/s12017-012-8198-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 22961555 ● Summary page in Scopus @ Elsevier: 2-s2.0-84874752700 (Tokushima University Institutional Repository: 106144, DOI: 10.1007/s12017-012-8198-6, PubMed: 22961555, Elsevier: Scopus)
34.	Shinya Watanabe, Junichi Iga, Shusuke Numata, Masahito Nakataki, Toshihito Tanahashi, Mitsuo Itakura and Tetsuro Ohmori : Association Study of Fat-mass and Obesity-associated Gene and Body Mass Index in Japanese Patients with Schizophrenia and Healthy Subjects., Clinical Psychopharmacology and Neuroscience, Vol.10, No.3, 185-189, 2012. (Summary) Fat-mass and obesity-associated (FTO) gene is known to be involved in the pathophysiology of obesity and a single-nucleotide polymorphism (SNP) rs9939609 of FTO gene is repeatedly confirmed to be associated with body mass index (BMI) and obesity. The aim of this study is to elucidate effects of FTO gene polymorphism on BMI in Japanese patients with schizophrenia and healthy subjects. Three hundred fifty one patients with schizophrenia and 342 age- and sex-matched healthy subjects participated in the study. Information on BMI and antipsychotic medication was also collected from patients and healthy subjects. Genotype of the FTO SNP rs9939609 was determined by TaqMan SNP Genotyping Assays. There was no significant difference in BMI between patients and healthy subjects. No significant difference in BMI was observed among any medications. We observed no significant difference in rs9939609 allele frequencies between patients and healthy subjects. There was a significant difference in BMI between healthy subjects with risk (AA or TA) genotypes and those with TT genotype. We also observed a significant positive correlation between the number of risk allele (A allele) and BMI in healthy subjects. Our study suggested that FTO rs9939609 polymorphism might have some impacts on the BMI in healthy subjects, but might not have same impacts on the BMI of patients with schizophrenia. (Link to Publication Site) ● Publication site (DOI): 10.9758/cpn.2012.10.3.185 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23431037 ● Search Scopus @ Elsevier (PMID): 23431037 ● Search Scopus @ Elsevier (DOI): 10.9758/cpn.2012.10.3.185 (DOI: 10.9758/cpn.2012.10.3.185, PubMed: 23431037)
35.	Tsunehiko Tanaka, Masahito Tomotake, Yoshinori Ueoka, Yasuhiro Kaneda, Kyoko Taniguchi, Masahito Nakataki, Shusuke Numata, Shinya Tayoshi, Ken Yamauchi, Satsuki Sumitani, Takashi Ohmori, Shu-ichi Ueno and Tetsuro Ohmori : Clinical correlates associated with cognitive dysfunction in people with schizophrenia., Psychiatry and Clinical Neurosciences, Vol.66, No.6, 491-498, 2012. (Link to Publication Site) ● Publication site (DOI): 10.1111/j.1440-1819.2012.02390.x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23066766 ● Search Scopus @ Elsevier (PMID): 23066766 ● Search Scopus @ Elsevier (DOI): 10.1111/j.1440-1819.2012.02390.x (DOI: 10.1111/j.1440-1819.2012.02390.x, PubMed: 23066766)
36.	Makoto Kinoshita, Masahito Nakataki, Satsuki Sumitani and Tetsuro Ohmori : 両側視床下核深部脳刺激術を施行され左側電極Onによってうつ状態から躁状態に転じたパーキンソン病の一例, Psychiatria et Neurologia Japonica, Vol.114, No.4, 468, 2012.
37.	Masahito Nakataki and Tetsuro Ohmori : 興奮性アミノ酸仮説に基づく統合失調症の薬物療法の試み NMDA受容体フルアゴニスト(グリシン，D-セリン，D-アラニン)の臨床エビデンス, Rinsyo Seisin Yakuri, Vol.15, No.5, 679-686, 2012.
38.	Ryoma Morigaki, Toshitaka Kawarai, Masahito Nakataki, Junichi Iga, Wataru Sako, Yoshifumi Mizobuchi, Shinji Nagahiro, Satoshi Goto and Ryuji Kaji : Clinical characteristics of X-linked dystonia-parkinsonism, Functional Neurosurgery, Vol.50, 150-153, 2011. (Keyword) X-linked dystonia parkinsonism / DYT3 / Clinical symptoms / Adaptibity of daily life / Striatal compartments (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1571135651154880768 (CiNii: 1571135651154880768)
39.	Kumiko Kikuchi, Junichi Iga, Sumiko Tayoshi, Masahito Nakataki, Shinya Watanabe, Shusuke Numata and Tetsuro Ohmori : Lithium decreases VEGF mRNA expression in leukocytes of healthy subjects and patients with bipolar disorder., Human Psychopharmacology, Vol.26, No.4-5, 358-363, 2011. (Summary) OBJECTIVES: Vascular endothelial growth factor (VEGF) is thought to be involved in the pathophysiology of mood disorders and the target of antidepressants. The aim of this study was to elucidate molecular effects of lithium on VEGF expression by using leukocytes of healthy subjects and patients with bipolar disorder. METHODS: Eight healthy male subjects participated in the first study. Lithium was prescribed for 2 weeks, enough to reach therapeutic serum concentration. Leukocyte counts and serum lithium concentrations were determined at baseline, at 1- and 2-week medication, and at 2 weeks after stopping medication. VEGF mRNA levels were also examined in nine lithium-treated bipolar patients and healthy controls in the second study. RESULTS: In the first study, leukocyte counts were significantly increased at 2 weeks compared with those at baseline and were normalized after 2 weeks. VEGF mRNA levels were significantly decreased at 2 weeks and after 2 weeks compared with those at baseline. Consistent with the first study, VEGF mRNA levels were significantly decreased in the lithium-treated bipolar patients compared with healthy controls. CONCLUSIONS: Our investigation suggests that VEGF mRNA expression may be useful as a peripheral marker of the effects of lithium. Copyright © 2011 John Wiley & Sons, Ltd. (Keyword) Adult / Antimanic Agents / Biological Markers / Bipolar Disorder / Diagnostic and Statistical Manual of Mental Disorders / Down-Regulation / Female / Humans / Leukocyte Count / Leukocytes / Lithium / Lithium Chloride / Male / Middle Aged / RNA, Messenger / Vascular Endothelial Growth Factor A (Tokushima University Institutional Repository) ● Metadata: 106306 (Link to Publication Site) ● Publication site (DOI): 10.1002/hup.1215 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21721043 ● Search Scopus @ Elsevier (PMID): 21721043 ● Search Scopus @ Elsevier (DOI): 10.1002/hup.1215 (Tokushima University Institutional Repository: 106306, DOI: 10.1002/hup.1215, PubMed: 21721043)
40.	Masahito Nakataki, Junichi Iga, Shusuke Numata, Eriko Yoshimoto, Kanami Kodera, Shinya Watanabe, Hongwei Song, Shu-ichi Ueno and Tetsuro Ohmori : Gene expression and association analysis of the epithelial membrane protein 1 gene in major depressive disorder in the Japanese population., Neuroscience Letters, Vol.489, No.2, 126-130, 2011. (Summary) The epithelial membrane protein 1 (EMP1) plays a role in neuronal differentiation and neurite outgrowth, which are involved in the pathogenesis of major depressive disorder (MDD). We sought to determine whether the EMP1 gene is implicated in MDD. We determined the mRNA expression levels of the EMP1 gene in peripheral-blood leukocytes of patients and control subjects (n=27 each). Next, we performed case-control association analyses (MDD, n=182; controls, n=350) in the Japanese population. The level of expression of the EMP1 mRNA was significantly lower in medication-free patients compared with control subjects (P<0.001). The association analysis revealed an absence of association between the polymorphisms studied and MDD, whereas a gender-specific association was observed between male controls and male patients for marker rs7315725 (permutation P=0.039). Our results suggest that the EMP1 gene may be implicated in the pathophysiology of MDD in the Japanese population. (Keyword) Adult / Case-Control Studies / Depressive Disorder, Major / Female / Genetic Association Studies / Humans / Japan / Leukocytes, Mononuclear / Male / Neoplasm Proteins / RNA, Messenger / Receptors, Cell Surface (Link to Publication Site) ● Publication site (DOI): 10.1016/j.neulet.2010.12.001 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 21146590 ● Search Scopus @ Elsevier (PMID): 21146590 ● Search Scopus @ Elsevier (DOI): 10.1016/j.neulet.2010.12.001 (DOI: 10.1016/j.neulet.2010.12.001, PubMed: 21146590)
41.	Yoshinori Ueoka, Masahito Tomotake, Tsunehiko Tanaka, Yasuhiro Kaneda, Kyoko Taniguchi, Masahito Nakataki, Shusuke Numata, Shinya Tayoshi, Ken Yamauchi, Satsuki Sumitani, Takashi Ohmori, Shu-ichi Ueno and Tetsuro Ohmori : Quality of life and cognitive dysfunction in people with schizophrenia, Progress in Neuro-Psychopharmacology & Biological Psychiatry, Vol.35, No.1, 53-59, 2011. (Summary) The main purpose of the present study was to examine the relationship between quality of life (QOL) and cognitive dysfunction in schizophrenia. Subjects were 61 stabilized outpatients. Quality of life and cognitive function were assessed using the Quality of Life Scale (QLS) and the Brief Assessment of Cognition in Schizophrenia (BACS), respectively. Clinical symptoms were evaluated with the Positive and Negative Syndrome Scale (PANSS) and the Calgary Depression Scale for Schizophrenia (CDSS). The BACS composite score and the BACS Verbal memory score were positively correlated with the QLS total score and two subscales. The BACS Attention and speed of information processing score had positive correlation with the QLS total and all the subscales scores. The PANSS Positive and Negative syndrome scores also had significant correlations with the QLS total score and all of the subscales. In addition, the CDSS score was negatively correlated with the QLS total score and some of the subscales. Stepwise regression analysis showed that the BACS Attention and speed of information processing score was an independent predictor of the QLS total score but it was less associated with the QLS than the PANSS Negative syndrome score and the CDSS score. The results suggest that negative and depressive symptoms are important factors on patients' QOL and also support the view that cognitive performance provides a determinant of QOL in patients with schizophrenia. (Keyword) Adult / Cognition Disorders / Female / Humans / Male / Middle Aged / Neuropsychological Tests / Predictive Value of Tests / Psychiatric Status Rating Scales / Quality of Life / Questionnaires / Retrospective Studies / Schizophrenia / Young Adult (Link to Publication Site) ● Publication site (DOI): 10.1016/j.pnpbp.2010.08.018 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20804809 ● Summary page in Scopus @ Elsevier: 2-s2.0-78650960902 (DOI: 10.1016/j.pnpbp.2010.08.018, PubMed: 20804809, Elsevier: Scopus)
42.	Shinya Tayoshi, Masahito Nakataki, Satsuki Sumitani, Kyoko Taniguchi, Sumiko Tayoshi, Shusuke Numata, Junichi Iga, Shu-ichi Ueno, Masafumi Harada and Tetsuro Ohmori : GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study., Schizophrenia Research, Vol.117, No.1, 83-91, 2010. (Summary) Gamma-amino butyric acid (GABA) is thought to play a role in the pathophysiology of schizophrenia. High magnetic field proton magnetic resonance spectroscopy ((1)H-MRS) provides a reliable measurement of GABA in specific regions of the brain. This study measured GABA concentration in the anterior cingulate cortex (ACC) and in the left basal ganglia (ltBG) in 38 patients with chronic schizophrenia and 29 healthy control subjects. There was no significant difference in GABA concentration between the schizophrenia patients and the healthy controls in either the ACC (1.36+/-0.45 mmol/l in schizophrenia patients and 1.52+/-0.54 mmol/l in control subjects) or the ltBG (1.13+/-0.26 mmol/l in schizophrenia patients and 1.18+/-0.20 mmol/l in control subjects). Among the right handed schizophrenia patients, the GABA concentration in the ltBG was significantly higher in patients taking typical antipsychotics (1.25+/-0.24 mmol/l) than in those taking atypical antipsychotics (1.03+/-0.24 mmol/l, p=0.026). In the ACC, the GABA concentration was negatively correlated with the dose of the antipsychotics (rs=-0.347, p=0.035). In the ltBG, the GABA concentration was positively correlated with the dose of the anticholinergics (rs=0.403, p=0.015). To the best of our knowledge, this is the first study to have directly measured GABA concentrations in schizophrenia patients using (1)H-MRS. Our results suggest that there are no differences in GABA concentrations in the ACC or the ltBG of schizophrenia patients compared to healthy controls. Antipsychotic medication may cause changes in GABA concentration, and atypical and typical antipsychotics may have differing effects. It is possible that medication effects conceal inherent differences in GABA concentrations between schizophrenia patients and healthy controls. (Keyword) Adult / Antipsychotic Agents / brain / Chronic Disease / Female / Humans / Magnetic Resonance Spectroscopy / Male / Protons / schizophrenia / gamma-Aminobutyric Acid (Link to Publication Site) ● Publication site (DOI): 10.1016/j.schres.2009.11.011 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 20022731 ● Search Scopus @ Elsevier (PMID): 20022731 ● Search Scopus @ Elsevier (DOI): 10.1016/j.schres.2009.11.011 (DOI: 10.1016/j.schres.2009.11.011, PubMed: 20022731)
43.	Shusuke Numata, Masahito Nakataki, Junichi Iga, Toshihito Tanahashi, Yoshihiro Nakadoi, Kazutaka Ohi, Ryota Hashimoto, Masatoshi Takeda, Mitsuo Itakura, Shu-ichi Ueno and Tetsuro Ohmori : Association Study Between the Pericentrin (PCNT) Gene and Schizophrenia., NeuroMolecular Medicine, Vol.12, No.3, 243-247, 2009. (Summary) Disrupted-in-schizophrenia 1 (DISC1), a known genetic risk factor for schizophrenia (SZ) and major depressive disorder (MDD), interacts with several proteins and some of them are reported to be genetically associated with SZ. Pericentrin (PCNT) also interacts with DISC1 and recently single-nucleotide polymorphisms (SNPs) within the PCNT gene have been found to show significant associations with SZ and MDD. In this study, case-controlled association analysis was performed to determine if the PCNT gene is implicated in SZ. Nine SNPs were analyzed in 1,477 individuals (726 patients with SZ and 751 healthy controls). No significant difference was observed between the controls and the patients in allelic frequencies or genotypic distributions of eight SNPs. Although allelic distribution of rs11702684 was different between the two groups (P = 0.042), the difference did not reach statistical significance after permutation correction for multiple comparisons. In the haplotypic analysis, we could not find any significant association in our subjects, either. This gene may not play a major role independently in the etiology of SZ in the Japanese population. (Link to Publication Site) ● Publication site (DOI): 10.1007/s12017-009-8106-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19937158 ● Search Scopus @ Elsevier (PMID): 19937158 ● Search Scopus @ Elsevier (DOI): 10.1007/s12017-009-8106-x (DOI: 10.1007/s12017-009-8106-x, PubMed: 19937158)
44.	Masahito Nakataki, Shusuke Numata, Junichi Iga, Shin'ya Tayoshi, Sumiko Tayoshi-Shibuya, Hongwei Song, Toshihito Tanahashi, Mitsuo Itakura, Shu-ichi Ueno and Tetsuro Ohmori : No association between Rho-associated coiled-coil forming protein serine/threonine kinase1 gene and schizophrenia in the Japanese population., Psychiatric Genetics, Vol.19, No.3, 162, 2009. (Link to Publication Site) ● Publication site (DOI): 10.1097/YPG.0b013e32832a5030 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19404162 ● Search Scopus @ Elsevier (PMID): 19404162 ● Search Scopus @ Elsevier (DOI): 10.1097/YPG.0b013e32832a5030 (DOI: 10.1097/YPG.0b013e32832a5030, PubMed: 19404162)
45.	Shusuke Numata, Junichi Iga, Masahito Nakataki, Shinya Tayoshi, Kyoko Taniguchi, Satsuki Sumitani, Masahito Tomotake, Toshihito Tanahashi, Mitsuo Itakura, Yoko Kamegaya, Masahiko Tsutsumi, Akira Sano, Takashi Asada, Hiroshi Kunugi, Shu-ichi Ueno and Tetsuro Ohmori : Gene expression and association analyses of the phosphodiesterase 4B (PDE4B) gene in major depressive disorder in the Japanese population., American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, Vol.150B, No.4, 527-534, 2009. (Summary) The phosphodiesterase 4B (PDE4B) interacts with disrupted-in-schizophrenia 1 (DISC1), which is a known genetic risk factor for schizophrenia, bipolar disorder and major depressive disorder (MDD). PDE4B is also important in the regulation of cAMP signaling, a second messenger implicated in learning, memory, and mood. In this study, we determined mRNA expression levels of the PDE4B gene in the peripheral blood leukocytes of patients with MDD and control subjects (n = 33, each). Next we performed two-stage case-controlled association analyses (first set; case = 174, controls = 348; second set; case = 481, controls = 812) in the Japanese population to determine if the PDE4B gene is implicated in MDD. In the leukocytes, a significantly higher expression of the PDE4B mRNA was observed in the drug-naïve MDD patients compared with control subjects (P < 0.0001) and the expression of the MDD patients significantly decreased after antidepressant treatment (P = 0.030). In the association analysis, we observed significant allelic associations of four SNPs (the most significant, rs472952; P = 0.002) and a significant haplotypic association (permutation P = 0.019) between the PDE4B gene and MDD in the first-set samples. However, we could not confirm these significant associations in the following independent second-set of samples. Our results suggest that the PDE4B gene itself does not link to MDD but the elevated mRNA levels of PDE4B might be implicated in the pathophysiology of MDD. (Keyword) Adult / Aged / Alleles / Case-Control Studies / Cyclic Nucleotide Phosphodiesterases, Type 4 / Depressive Disorder, Major / Female / Gene Expression / Gene Frequency / Genetic Predisposition to Disease / Genotype / Haplotypes / Humans / Japan / Male / Middle Aged / RNA, Messenger (Link to Publication Site) ● Publication site (DOI): 10.1002/ajmg.b.30852 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 18785206 ● Search Scopus @ Elsevier (PMID): 18785206 ● Search Scopus @ Elsevier (DOI): 10.1002/ajmg.b.30852 (DOI: 10.1002/ajmg.b.30852, PubMed: 18785206)
46.	Shusuke Numata, Junichi Iga, Masahito Nakataki, Shinya Tayoshi, Toshihito Tanahashi, Mitsuo Itakura, Shu-ichi Ueno and Tetsuro Ohmori : Positive association of the pericentrin (PCNT) gene with major depressive disorder in the Japanese population., Journal of Psychiatry & Neuroscience, Vol.34, No.3, 195-198, 2009. (Summary) BACKGROUND: Pericentrin (PCNT) interacts with disruption-in-schizophrenia 1 (DISC1), a known genetic risk factor for schizophrenia, bipolar disorder and major depressive disorder (MDD). We sought to determine whether the PCNT gene is implicated in MDD. METHODS: We performed case-control association analyses in the Japanese population. We analyzed 9 single nucleotide polymorphisms (SNPs) in 173 patients with MDD and 348 healthy controls. RESULTS: We found a significant allelic association between 3 SNPs (rs3788265, rs2073376 and rs2073380) of the PCNT gene and MDD (p = 0.006, 0.005 and 0.021, respectively). After correction for multiple testing, 2 SNPs (rs3788265 and rs2073376) retained significant allelic associations with MDD. In addition, we found a significant association between the 2 marker haplotypes (r3788265 and rs2073376) and MDD (permutation p = 0.011). LIMITATIONS: Our sample was small and comprised only Japanese participants. In addition, owing to the late onset of MDD, it is possible that the disorder will develop in at least some participants in our control group. Finally, we did not show how SNPs of the PCNT gene alter its function. CONCLUSION: Our results suggest that genetic variations in the PCNT gene may play a significant role in the etiology of MDD in the Japanese population. (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19448849 ● Search Scopus @ Elsevier (PMID): 19448849 (PubMed: 19448849)
47.	Shin'Ya Tayoshi, Satsuki Sumitani, Kyoko Taniguchi, Sumiko Shibuya-Tayoshi, Shusuke Numata, Jun-ichi Iga, Masahito Nakataki, Shu-ichi Ueno, Masafumi Harada and Tetsuro Ohmori : Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (1H-MRS)., Schizophrenia Research, Vol.108, No.1-3, 69-77, 2008. (Summary) A change in the glutamatergic system is thought to play an important role in the pathophysiology of schizophrenia. The aim of this study was to investigate the changes in metabolites, including glutamate (Glu), in the anterior cingulate cortex (ACC) and the left basal ganglia (ltBG) of patients with chronic schizophrenia using proton magnetic resonance spectroscopy ((1)H-MRS). In addition, since gender differences in this illness were known, we examined the effects of gender on these metabolites. The (1)H-MRS was performed on the ACC and ltBG of 30 patients with schizophrenia and 25 healthy individuals who acted as the control group. The levels of Glu, glutamine (Gln), creatine plus phosphocreatine (Cre), myo-inositol (mI), N-acetylaspartate (NAA), and choline-containing compounds (Cho) were measured. Two-way analysis of variance revealed that the illness significantly affected the levels of Glu and mI in the ACC; both metabolites were lower in the patients with schizophrenia as compared to the control subjects. The results also revealed that gender significantly affected the level of Gln in the ACC and the levels of Cre and NAA in the ltBG; the level of Gln in the ACC were higher in male subjects versus female subjects, whereas Cre and NAA levels in the ltBG were lower in male subjects as compared to female subjects. These results confirmed a change in the glutamatergic system and suggested an involvement of mI in the pathophysiology of schizophrenia. (Keyword) Adult / Analysis of Variance / Aspartic Acid / Basal Ganglia / Choline / Creatine / Female / Glutamic Acid / Gyrus Cinguli / Humans / Image Processing, Computer-Assisted / Inositol / Magnetic Resonance Spectroscopy / Male / Middle Aged / Protons / schizophrenia / Sex Characteristics / Young Adult (Link to Publication Site) ● Publication site (DOI): 10.1016/j.schres.2008.11.014 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 19097753 ● Search Scopus @ Elsevier (PMID): 19097753 ● Search Scopus @ Elsevier (DOI): 10.1016/j.schres.2008.11.014 (DOI: 10.1016/j.schres.2008.11.014, PubMed: 19097753)
48.	Shusuke Numata, Shu-ichi Ueno, Junichi Iga, Hongwei Song, Masahito Nakataki, Shinya Tayoshi, Satsuki Sumitani, Masahito Tomotake, Mitsuo Itakura, Akira Sano and Tetsuro Ohmori : Positive association of the PDE4B (phosphodiesterase 4B) gene with schizophrenia in the Japanese population., Journal of Psychiatric Research, Vol.43, No.1, 7-12, 2008. (Summary) The phosphodiesterase 4B (PDE4B) gene is located at 1p31, a susceptibility region for schizophrenia (SZ). Moreover, PDE4B interacts with DISC1, which is a known genetic risk factor for SZ. Recently, it was reported that the PDE4B gene is associated with SZ in Caucasian and African American populations. In this study, case-controlled association analyses were performed in the Japanese population to determine if the PDE4B gene is implicated in SZ. Thirteen single nucleotide polymorphisms (SNPs) were analyzed in 444 schizophrenic patients and 452 control subjects. Three SNPs (rs2180335, rs910694 and rs472952) were significantly associated with SZ after applying multiple test correction (p=0.039, 0.004 and 0.028). In addition, a significant association was found between specific haplotypes (rs2180335 and rs910694) and SZ (permutation p=0.001). Our result suggests that variations at the PDE4B locus may play a significant role in the etiology of SZ in the Japanese population. (Keyword) Asian Continental Ancestry Group / Case-Control Studies / Catechol O-Methyltransferase / Chromosome Mapping / Chromosomes, Human, Pair 1 / Control Groups / Cyclic Nucleotide Phosphodiesterases, Type 4 / Female / Gene Frequency / Genetic Markers / Genetic Predisposition to Disease / Genotype / Haplotypes / Humans / Linkage (Genetics) / Linkage Disequilibrium / Male / Middle Aged / Polymorphism, Single Nucleotide / Risk Factors / schizophrenia (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jpsychires.2008.01.013 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 18329668 ● Search Scopus @ Elsevier (PMID): 18329668 ● Search Scopus @ Elsevier (DOI): 10.1016/j.jpsychires.2008.01.013 (DOI: 10.1016/j.jpsychires.2008.01.013, PubMed: 18329668)
49.	Shusuke Numata, Shu-ichi Ueno, Junichi Iga, Masahito Nakataki, Toshihito Tanahashi, Mitsuo Itakura, Akira Sano, Kazutaka Ohi, Ryota Hashimoto, Masatoshi Takada and Tetsuro Ohmori : No association between the NDE1 gene and schizophrenia in the Japanese population., Schizophrenia Research, Vol.99, No.1-3, 367-369, 2008. (Keyword) Adult / Aged / Alleles / Asian Continental Ancestry Group / Female / Gene Frequency / Genetic Predisposition to Disease / Genetics, Population / Genotype / Humans / Male / Microtubule-Associated Proteins / Middle Aged / Polymorphism, Single Nucleotide / schizophrenia (Link to Publication Site) ● Publication site (DOI): 10.1016/j.schres.2007.10.032 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 18178387 ● Search Scopus @ Elsevier (PMID): 18178387 ● Search Scopus @ Elsevier (DOI): 10.1016/j.schres.2007.10.032 (DOI: 10.1016/j.schres.2007.10.032, PubMed: 18178387)
50.	Junichi Iga, Shu-ichi Ueno, Ken Yamauchi, Shusuke Numata, Sumiko Tayoshi-Shibuya, Sawako Kinouchi, Masahito Nakataki, Hongwei Song, Kazuhiko Hokoishi, Hirotaka Tanabe, Akira Sano and Tetsuro Ohmori : The Val66Met polymorphism of the brain-derived neurotrophic factor gene is associated with psychotic feature and suicidal behavior in Japanese major depressive patients, American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics, Vol.144, No.8, 1003-1006, 2007. (Summary) Recent researches have suggested that brain-derived neurotrophic factor (BDNF) may be implicated in the pathophysiology of mood disorder. This study examined the association between the BDNF Val66Met polymorphism and major depressive disorder (MDD) in a Japanese population. We genotyped the BDNF Val66Met polymorphism in 154 major depressive patients and 154 age- and sex-matched control subjects. The genotypic distributions and allele frequencies were similar among the patients and control subjects. When the relationships of the polymorphism with several clinical variables (i.e., age, sex, age of onset, number of episode, presence of psychotic features, suicidal behavior, and family history) were examined, the dose of Met allele had significant effects on psychotic feature and suicidal behavior and family history. These results suggest that the BDNF Val66Met polymorphism is not related to the development of MDD but related to clinical features of MDD in a Japanese population. (Keyword) Adult / Age Distribution / Age of Onset / Brain-Derived Neurotrophic Factor / Case-Control Studies / Depressive Disorder, Major / Diagnostic and Statistical Manual of Mental Disorders / Female / Humans / Male / Methionine / Middle Aged / Polymorphism, Genetic / Psychotic Disorders / Sex Distribution / Suicide / Valine (Link to Publication Site) ● Publication site (DOI): 10.1002/ajmg.b.30520 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 17510948 ● Search Scopus @ Elsevier (PMID): 17510948 ● Search Scopus @ Elsevier (DOI): 10.1002/ajmg.b.30520 (DOI: 10.1002/ajmg.b.30520, PubMed: 17510948)
51.	Hongwei Song, Shu-ichi Ueno, Shusuke Numata, Junichi Iga, Sumiko Tayoshi, Masahito Nakataki, Shin'Ya Tayoshi, Ken Yamauchi, Satsuki Sumitani, Tomohito Tomotake, Tomohito Tada, Toshihito Tanahashi, Mitsuo Itakura and Tetsuro Ohmori : Association between PNPO and schizophrenia in the Japanese population, Schizophrenia Research, Vol.97, No.1-3, 264-270, 2007. (Summary) Accumulating evidence suggests that both homocysteine metabolism and monoaminergic neurotransmitter systems are important in schizophrenia pathology. We hypothesized that the gene PNPO (pyridoxine 5'-phosphatase oxidase gene) might be a candidate for susceptibility to schizophrenia because PNPO encodes pyridoxamine 5'-phosphate oxidase (EC 1.4.3.5), a rate-limiting enzyme in pyridoxal 5'-phosphate (PLP, vitamin B(6)) synthesis. PLP is a metabolically-active form of vitamin B(6) and thus, is required as a co-factor for enzymes involved in both homocysteine metabolism and synthesis of neurotransmitters such as catecholamine. We examined 8 single nucleotide polymorphisms (SNPs) in PNPO and its 5'-flanking regions in 359 schizophrenia patients and 582 control subjects. Four marker regions of PNPO showed significant levels of allelic associations with schizophrenia (the highest was rs2325751, P=0.004). In addition, the haplotype case-control study revealed a significant association (permutation P<0.00001) between PNPO and schizophrenia. These findings suggest that variations in PNPO may contribute to overall genetic risk for schizophrenia in the Japanese population. (Keyword) Adult / Aged / Alleles / Asian Continental Ancestry Group / Female / Genetic Markers / Genetic Predisposition to Disease / Genotype / Haplotypes / Humans / Japan / Linkage Disequilibrium / Male / Middle Aged / Neurotransmitter Agents / Polymorphism, Single Nucleotide / Pyridoxaminephosphate Oxidase / Risk Factors / schizophrenia (Link to Publication Site) ● Publication site (DOI): 10.1016/j.schres.2007.08.004 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 17851041 ● Search Scopus @ Elsevier (PMID): 17851041 ● Search Scopus @ Elsevier (DOI): 10.1016/j.schres.2007.08.004 (DOI: 10.1016/j.schres.2007.08.004, PubMed: 17851041)
52.	Junichi Iga, Shu-ichi Ueno, Ken Yamauchi, Shusuke Numata, Sumiko Tayoshi, Sawako Kinouchi, Masahito Nakataki, Song Hongwei, Kazuhiko Hokoishi, Hirotaka Tanabe, Akira Sano and Tetsuro Ohmori : Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder, Progress in Neuro-Psychopharmacology & Biological Psychiatry, Vol.31, No.3, 658-663, 2007. (Summary) Vascular endothelial growth factor (VEGF) has been implicated in neuronal survival, neuroprotection, regeneration, growth, differentiation, and axonal outgrowth, which are known to be involved in the pathophysiology of major depressive disorder (MDD). Recently, the VEGF mRNA expression in the peripheral leukocytes from Alzheimer's disease or cardiovascular disease was reported to be changed. We hypothesized that the expression of the VEGF mRNA in the peripheral leukocytes may be a good candidate for the biological marker for MDD. Thirty two patients with MDD and age- and sex-matched control subjects were included in this expression study. The VEGF mRNA levels in the peripheral leukocytes from drug-naive MDD patients were significantly higher than those from the control subjects and the magnitude of the decrease of VEGF mRNA after 8-week treatment significantly correlated with clinical improvement. Then, we genotyped two single nucleotide polymorphic markers of VEGF gene, which were reported to be associated with amyotrophic lateral sclerosis and Alzheimer's disease, in patients with MDD and control subjects (n=154, each). We did not find any significant association between these markers and MDD or its clinical subtypes. Our investigation indicates that the higher expression levels of VEGF mRNA in the peripheral leukocytes are associated with the depressive state and their recovery after treatment may be associated with the clinical improvement. (Keyword) Adult / Antidepressive Agents, Second-Generation / Case-Control Studies / Depressive Disorder, Major / Female / Gene Expression Regulation / Genetic Predisposition to Disease / Humans / Leukocytes / Male / Middle Aged / Paroxetine / RNA, Messenger / Vascular Endothelial Growth Factor A (Link to Publication Site) ● Publication site (DOI): 10.1016/j.pnpbp.2006.12.011 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 17257729 ● Search Scopus @ Elsevier (PMID): 17257729 ● Search Scopus @ Elsevier (DOI): 10.1016/j.pnpbp.2006.12.011 (DOI: 10.1016/j.pnpbp.2006.12.011, PubMed: 17257729)

Academic Paper (Unrefereed Paper):

1.	井上麻由, 上田美香, Takashi Kaji, 黒濱綾子, 田山正伸, Ryuji Nakagawa, Masahito Nakataki, 橋本公子, 橋本直子, 春名充, Masahiko Maegawa, 松下由喜代, 宮上和美, Naoto Yonetani, Minoru Irahara and Mari Haku : 徳島県妊産婦メンタルケア対策早期発見と支援のポイント(解説), 徳島産婦人科医報, No.52, 130-149, 2019.

Academic Letter:

1.	Ryoma Morigaki, Masahito Nakataki, Toshitaka Kawarai, Lillian V. Lee, Rosalia A. Teleg, Ma Daisy P. Tabuena, Hideo Mure, Wataru Sako, Paul Matthew D. Pasco, Shinji Nagahiro, Junichi Iga, Tetsuro Ohmori, Satoshi Goto and Ryuji Kaji : Depression in X-linked dystonia-parkinsonism:A case-control study, Parkinsonism & Related Disorders, Vol.19, No.9, 844-846, 2013. (Keyword) Case-Control Studies / Depression / Dystonic Disorders / Genetic Diseases, X-Linked / Heredodegenerative Disorders, Nervous System / Humans / Male / Parkinson Disease (Link to Publication Site) ● Publication site (DOI): 10.1016/j.parkreldis.2013.04.027 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 23706616 ● Summary page in Scopus @ Elsevier: 2-s2.0-84880785140 (DOI: 10.1016/j.parkreldis.2013.04.027, PubMed: 23706616, Elsevier: Scopus)

Review, Commentary:

1.	Tomohiko Nakayama, Yukiko Tomioka, Naoki Yamada, Hidehiro Umehara, Makoto Kinoshita, Masahito Nakataki and Shusuke Numata : 臨床現場におけるたとえ話, Japanese Journal of Psychiatric Treatment, Vol.37, No.7, 745-749, Jul. 2022. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1520856045142110592 (CiNii: 1520856045142110592)
2.	Masahito Nakataki : 今さら聞けないこの言葉 NMDA受容体, 精神科臨床サービス, Vol.15, No.2, 238-239, 2015.
3.	Masahito Nakataki and Tetsuro Ohmori : Function of glutamate and GABA in schizophrenia, Japanese Journal of Biological Psychiatry, Vol.24, No.3, 145-152, 2013. (Keyword) 統合失調症 / グルタミン酸 / GABA / ¹H-MRS (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390282680389196928 (CiNii: 1390282680389196928)
4.	Masahito Nakataki and Tetsuro Ohmori : 精神科領域における画像診断の展望精神疾患とMRS, 最新精神医学, Vol.16, No.3, 303-309, 2011.
5.	Masahito Nakataki, Hiroko Kubo, Satsuki Sumitani and Tetsuro Ohmori : MRSを用いた統合失調症研究, Japanese Journal of Psychiatric Treatment, Vol.26, No.11, 1427-1433, 2011.
6.	Shu-ichi Ueno, Junichi Iga, Shusuke Numata, 宋鴻偉, Shinya Tayoshi, Masahito Nakataki, Ken Yamauchi and Tetsuro Ohmori : Genetic aspects of depressive disorder, Psychiatria et Neurologia Japonica, Vol.109, No.9, 859-863, Sep. 2007. (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1523388079950438144 ● Summary page in Scopus @ Elsevier: 2-s2.0-38749149592 (CiNii: 1523388079950438144, Elsevier: Scopus)

Proceeding of International Conference:

1.	Tomohiko Nakayama, Hiroaki Edo, Yoshida Tomohiro, Matsumoto Yui, Shinya Watanabe, Masahito Nakataki, Shusuke Numata and Tetsuro Ohmori : Nortriptyline Therapy of Treatment-Resistant Depression: two case reports, The CINP 2021 Virtual World Congress, Online, Feb. 2021.
2.	Shinya Watanabe, Hidehiro Umehara, Yukiko Tomioka, Makoto Kinoshita, Masahito Nakataki, Shusuke Numata and Tetsuro Ohmori : Effects of processing conditions on plasma L-glutamate levels in non-psychiatric healthy subjects., 6th Congress of AsCNP Asian College of Neuropsychopharmacology, Fukuoka, Oct. 2019.
3.	Masashi Ohta, Masahito Nakataki, Tomoya Takeda, Shusuke Numata, Takeo Tominaga, Naomi Kameoka, Hiroko Kubo, Makoto Kinoshita, Matsuura Kanae, Maki Ohtomo, Takeichi Naoya, Masafumi Harada and Tetsuro Ohmori : Causal relationship between salience network dysfunction, depressed mood, and subjective quality of life in schizophrenia., 6th Congress of AsCNP Asian College of Neuropsychopharmacology, Fukuoka, Oct. 2019.
4.	Yukiko Tomioka, Hidehiro Umehara, Shinya Watanabe, Masahito Nakataki, Masuda Rumiko, Kazuaki Mawatari, Takeshi Nikawa, Akira Takahashi, Shusuke Numata and Tetsuro Ohmori : Altered plasma metabolites related to one-carbon metabolism in schizophrenia., WFSBP Asia Pacific Regional Congress of Biological Psychiatry, Kobe, Sep. 2018.
5.	Masahito Nakataki : 1H-magnetic resonance spectroscopy study of Glutamate-related abnormality in bipolar disorder, WFSBP Asia Pacific Regional Congress of Biological Psychiatry, Kobe, Sep. 2018.
6.	Tomoya Takeda, Masahito Nakataki, Masashi Ohta, Hamatani Sayo, Matsuura Kanae, Yoshida Reona and Tetsuro Ohmori : Relationship clinical variables and positive self-thought in patients with schizophrenia., The 46th BABCP Annual Workshops and Conference, Glasgow, Scotland., Jul. 2018.
7.	Tomoya Takeda, Masahito Nakataki, Masashi Ohta, Hamatani Sayo, Matsuura Kanae and Tetsuro Ohmori : The effect of negative thoughts on QOL in patients with schizophrenia., The 45th BABCP Annual Workshops and Conference, Manchester, Jul. 2017.
8.	Masashi Ohta, Y Funakoshi, Masafumi Harada, Junichi Iga, Hiroko Kubo, Masahito Nakataki, C Nakayama, T Nishikawa, Shusuke Numata, Tetsuro Ohmori, Satsuki Sumitani, M Tamaru and A. Uezato : Structural and functional brain alterations in schizophrenia patients treated with D-cycloserine:a combination of VBM and resting-state functional connectivity study., 30th CINP World Congress of Neuropsychopharmacology, Seoul, Jul. 2016.
9.	Masahito Nakataki, Soravia M. Leila, Schwab Simon, Horn Helge, Dierks Thomas, Strik Werner, Wiest Roland, Heinrichs Markus, Quervain J.-F. de Dominique, Federspiel Andrea and Morishima Yosuke : Glucocorticoid administration improves aberrant fear processing networks in spider phobia, CINP 2016, Seoul, Jul. 2016.
10.	Tomoya Takeda, Satsuki Sumitani, Masahito Nakataki, Sayo Hamatani, Y Yokose, M Shikata and Tetsuro Ohmori : Relationship between WAIS- and AQ in Japanese ASD patients with average intelligence quotient., 31st International Congress of Psychology, Tokyo, Jul. 2016.
11.	Masahito Nakataki, M Harada and Tetsuro Ohmori : Glutamate and GABA concentrations in schizophrenia patients and the effects of antipsychotic medication: results from proton magnetic resonance spectroscopy studies., The 3rd Congress of Asian College of Neuropsychopharmacology, China, Sep. 2013.
12.	Masahito Nakataki, Satsuki Sumitani, Hiroko Kubo, Shusuke Numata, Junichi Iga, Shinya Watanabe, Makoto Kinoshita, Masafumi Harada and Tetsuro Ohmori : Structural brain asymmetry in obsessive-compulsive disorder., 11th world congress of biological psychiatry, Kyoto, Jun. 2013.
13.	Masahito Nakataki, Satsuki Sumitani, Hiroko Kubo, Masafumi Harada and Tetsuro Ohmori : Caudate asymmetry in obesessive compulsive disorder: A voxel based morphometry study, 28th CINP World Congress of Neuropsychopharmacology, Stockholm, Jun. 2012.
14.	Masahito Nakataki, Shinya Tayoshi, Hiroko Kubo, Junichi Iga, Shinya Watanabe, Satsuki Sumitani, Masafumi Harada and Tetsuro Ohmori : Amino acid neurotransmission in schizophrenia patients and the effects of antipsychotic medication: A proton magnetic resonance spectroscopy study, 10th World Conbress of Biological Psychiatry, Prague, Czech Republic, Jun. 2011.
15.	Shinya Watanabe, Junichi Iga, Masahito Nakataki, Shusuke Numata, 菊地久美子 and Tetsuro Ohmori : Association study of fat-mass and obesity-associated(FTO) gene and body mass index in a Japanese schizophrenia and healthy Japanese population, 10th World Conbress of Biological Psychiatry, Prague, Czech Republic, May 2011.
16.	Junichi Iga, 菊地久美子, Shinya Tayoshi, Masahito Nakataki, Shinya Watanabe, Shusuke Numata and Tetsuro Ohmori : SOCS3, a candidate gene for the molecular effects of lithium and pathophysiology of MDD, 10th World Conbress of Biological Psychiatry, Prague, Czech Republic, May 2011.
17.	菊地久美子, Junichi Iga, Shinya Tayoshi, Masahito Nakataki, Shinya Watanabe, Shusuke Numata and Tetsuro Ohmori : Lithium decreases VEGF mRNA expression in leukocytes of healthy subjects., XXVII CINP CONGRESS 2010 WORLD CONGRESS, Hong Kong, Jun. 2010.
18.	Junichi Iga, 菊地久美子, Sumiko Tayoshi, Masahito Nakataki, Shinya Watanabe, Shusuke Numata and Tetsuro Ohmori : Effect of lithium on gene expression in leukocytes of healthy subjects., XXVII CINP CONGRESS 2010 WORLD CONGRESS, Hong Kong, Jun. 2010.
19.	Masahito Nakataki, Junichi Iga, Shusuke Numata, E Yoshimoto, K Kodera, Shinya Watanabe, H Song, S Ueno and Tetsuro Ohmori : Gene expression and association analysis of the epithelial membrane protein 1 gene in major depressive disorder in the Japanese population, XXVII CINP CONGRESS 2010 WORLD CONGRESS, Hong Kong, Jun. 2010.
20.	Shinya Watanabe, Junichi Iga, Masahito Nakataki, Shusuke Numata, Kumiko Kikuchi and Tetsuro Ohmori : Association study of cannabinoid receptor 1 gene and schizophrenia and body mass index in a Japanese population, XXVII CINP CONGRESS 2010 WORLD CONGRESS, Hong Kong, Jun. 2010.
21.	Yoshinori Ueoka, Masahito Tomotake, Tsunehiko Tanaka, Yasuhiro Kaneda, Masahito Nakataki, Satsuki Sumitani, Shu-ichi Ueno and Tetsuro Ohmori : Quality of Life and Cognitive Dysfunction in People with Schizophrenia, The 1st Meeting of the Asian College of Neuropsychopharmacology, Nov. 2009.
22.	Masahito Tomotake, Yoshinori Ueoka, Tsunehiko Tanaka, Yasuhiro Kaneda, Ken Yamauchi, Kyoko Taniguchi, Yumiko Takikawa, Masahito Nakataki, Shusuke Numata, Shinya Tayoshi, Satsuki Sumitani, Yumiko Izaki, Takashi Ohmori, Shu-ichi Ueno and Tetsuro Ohmori : Subjective quality of life and cognitive function in people with schizophrenia, XIV World Congress of Psychiatry, Sep. 2008.
23.	Yoshinori Ueoka, Masahito Tomotake, Tsunehiko Tanaka, Yasuhiro Kaneda, Ken Yamauchi, Kyoko Taniguchi, Yumiko Takikawa, Masahito Nakataki, Shusuke Numata, Shinya Tayoshi, Satsuki Sumitani, Yumiko Izaki, Takashi Ohmori, Shu-ichi Ueno and Tetsuro Ohmori : Predictors of objective quality of life in people with schizophrenia, XIV World Congress of Psychiatry, Sep. 2008.
24.	Masahito Nakataki, Junichi Iga, Shu-ichi Ueno, K Yamauchi, Shusuke Numata, S Tayoshi-Shibuya, S Kinouhci, H Song, K Hokoishi, H Tanabe, A Sano and Tetsuro Ohmori : Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder., Neuroscience, SanDiego, USA, Nov. 2007.
25.	Shusuke Numata, Shu-ichi Ueno, Junichi Iga, Song Hongwei, Masahito Nakataki, Mitsuo Itakura, Akira Sano and Tetsuro Ohmori : Positive Association of The PDE4B (Phosphodiesterase 4B) gene with Schizophrenia in the Japanese Population, Neuroscience, San Diego, USA, Nov. 2007.

Proceeding of Domestic Conference:

1.	Kotaro Kashihara, Toshiki Takanabe, Keita Kiuchi, Hidehiro Umehara, Koshi Irizawa, Masahito Nakataki, Shusuke Numata, XIN KANG, Minoru Yoshida and Kazuyuki Matsumoto : Constructing multimodal counseling dataset for depression detection and feature analysis, IT healthcare, Vol.19, No.1, 94-99, Aug. 2024. (Summary) In recent years, depression caused by stress and anxiety has been on the rise worldwide, and the number of people taking leave due to depression and other mental illnesses has been increasing in Japan as well. However, there is a serious shortage of counselors and psychiatrists, making early detection difficult. In this study, for early detection of depression, 25 Japanese university students were interviewed by a professional counselor for about 30 minutes, and a multimodal dataset consisting of verbal, audio, video, and heart rate data was constructed during the interview. Before and after the interviews, a questionnaire about the subjects' current psychological state was also administered. The constructed dataset was analyzed by extracting features using GiNZA, OpenSMILE, and OpenFace, and comparing them with the results of the questionnaire. In the future, we plan to conduct interviews with mentally ill subjects and collect data from them. (Keyword) multimodal dataset / depression detection / dataset
2.	Yui Matsumoto, Masahito Nakataki, 石本良祐, 一宮俊文, 野田尚吾, 前田拓也, 増田太利志, Tomohiro Yoshida, Shun Aoi, Naoki Yamada, Yukiko Tomioka, Hidehiro Umehara, 土師正太郎, Koji Fujita, Yuishin Izumi and Shusuke Numata : ADの灰白質体積と神経心理検査および髄液アミロイドβの関連性の検討, 【第42回日本認知症学会学術総会, Nov. 2023.
3.	Tomohiko Nakayama, Yui Matsumoto, Yukiko Tomioka, Naoki Yamada, Masahito Nakataki and Shusuke Numata : 長期間維持電気けいれん療法を施行している遅発緊張病の一例, 第36回日本総合病院精神医学会総会, Nov. 2023.
4.	塩田恭史, Tomohiko Nakayama, Naoki Yamada, Masahito Nakataki and Shusuke Numata : 脳梗塞と転換症状の鑑別を要したうつ病の一例, 第63回中国・四国精神神経学会, Nov. 2023.
5.	大西将統, Yui Matsumoto, Naoki Yamada, Masahito Nakataki and Shusuke Numata : 入院治療が奏功した思春期の神経性無食欲症の1例, 第63回中国・四国精神神経学会, Nov. 2023.
6.	青山理央, Yui Matsumoto, Naoki Yamada, Masahito Nakataki and Shusuke Numata : パーキンソン病に対するDBS治療中に生じた希死念慮から自殺企図に至った一例, 第63回中国・四国精神神経学会, Nov. 2023.
7.	伊藤颯姫, 松本純弥, 福永雅喜, 三浦健一郎, 根本清貴, 岡田直大, 橋本直樹, 森田健太郎, 越山太輔, 大井一高, 高橋努, 肥田道彦, 山森英長, 藤本美智子, 安田由華, 伊藤颯姫, 山﨑龍一, 長谷川尚美, 成田尚, 横山仁史, 三嶋亮, 宮田淳, 小林祐子, 笹林大樹, 原田健一郎, 山本真江里, 平野羊嗣, 板橋貴史, Masahito Nakataki, 橋本龍一郎, タキンキン, 小池進介, 松原敏郎, 岡田剛, 吉村玲児, 阿部修, 鬼塚俊明, 渡邊嘉之, 松尾幸治, 山末英典, 岡本泰昌, 鈴木道雄, 尾崎紀夫, 笠井清登 and 橋本亮太 : 多施設共同研究によるdrug freeの統合失調症患者における大脳皮質構造への疾患の効果の検討, 第45回日本生物学的精神医学会年会, Nov. 2023.
8.	松本純弥, 福永雅喜, 三浦健一郎, 根本清貴, 岡田直大, 橋本直樹, 森田健太郎, 越山太輔, 大井一高, 高橋努, 肥田道彦, 山森英長, 藤本美智子, 安田由華, 伊藤颯姫, 山﨑龍一, 長谷川尚美, 成田尚, 横山仁史, 三嶋亮, 宮田淳, 小林祐子, 笹林大樹, 原田健一郎, 山本真江里, 平野羊嗣, 板橋貴史, Masahito Nakataki, 橋本龍一郎, タキンキン, 小池進介, 松原敏郎, 岡田剛, 吉村玲児, 阿部修, 鬼塚俊明, 渡邊嘉之, 松尾幸治, 山末英典, 岡本泰昌, 鈴木道雄, 尾崎紀夫, 笠井清登 and 橋本亮太 : 児童思春期発症のうつ病の多施設大規模データによる大脳皮質構造解析, 第45回日本生物学的精神医学会年会, Nov. 2023.
9.	Yui Matsumoto, Masahito Nakataki, 石本良祐, 一宮俊文, 野田尚吾, 前田拓也, 増田太利志, Tomohiro Yoshida, Shun Aoi, Naoki Yamada, Yukiko Tomioka, Hidehiro Umehara, 土師正太郎, Koji Fujita, Yuishin Izumi and Shusuke Numata : 認知症の灰白質体積と神経心理検査および髄液アミロイドβの関連性の検討, 第45回日本生物学的精神医学会年会, Nov. 2023.
10.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, Yui Matsumoto, Tomohiro Yoshida, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Akira Takahashi, 岡本泰昌 and Shusuke Numata : 大うつ病性障害患者における治療前後の血中代謝物濃度の変化, 第45回日本生物学的精神医学会年会, Nov. 2023.
11.	Yoshiteru Tada, Toshitaka Fujihara, 泉千恵, 福田直也, Masahito Nakataki, Tatsuo Mori, Hiroki Yamazaki and Yasushi Takagi : 「誰も取り残さない」てんかんの医療費助成・福祉サービスの提供, 第56回日本てんかん学会学術集会, Oct. 2023.
12.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, Yui Matsumoto, Tomohiro Yoshida, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Akira Takahashi, 岡本泰昌 and Shusuke Numata : 双極性障害における血中代謝物の変化, 第33回日本臨床精神神経薬理学会学術集会, Sep. 2023.
13.	橋本直樹, 根本清貴, 福永雅喜, 松本純弥, 三浦健一郎, 岡田直大, 森田健太郎, 越山太輔, 大井一高, 高橋努肥, 田道彦, 山森英長, 藤本美智子, 安田由華, 長谷川尚美, 伊藤颯姫, 成田尚, 横山仁史, 三嶋亮, 河島孝彦, 小林祐子, 笹林大樹, 原田健一郎, 山本真江里, 平野羊嗣, 板橋貴史, Masahito Nakataki, 橋本龍一郎, タキンキン, 小池進介, 松原敏郎, 岡田剛, 吉村玲児, 阿部修, 鬼塚俊明, 渡邊嘉之, 松尾幸治, 山末英典, 岡本泰昌, 鈴木道雄, 尾崎紀夫, 笠井清登 and 橋本亮太 : 脳構造画像を用いた統合失調症らしさのメガアナライシス, 第17回日本統合失調症学会, Mar. 2023.
14.	Tatsuo Mori, Yoshiteru Tada, Masahito Nakataki, Takahiro Tayama, Aya Gohji, Yoshihiro Touda, Toshitaka Fujihara, Hiroki Yamazaki and Kenji Mori : 徳島大学病院てんかんセンターにおけるトランジションの現状と今後の課題, 第10回全国てんかんセンター協議会総会栃木大会 2023, Mar. 2023.
15.	Yoshiteru Tada, Masahito Nakataki, Tatsuo Mori, Toshitaka Fujihara, Aya Gohji, Hiroki Yamazaki, 泉千恵, 高尾里沙, 多田雅美, 阿部修司, Kenji Mori and Yasushi Takagi : 地方におけるてんかん支援拠点病院の役割, 第10回全国てんかんセンター協議会, Feb. 2023.
16.	Ryoma Morigaki, Kazuhisa Miyake, Taku Matsuda, KOYAMA Hiroshi, Ryosuke Miyamoto, Yuishin Izumi, Masahito Nakataki, Ryuji Kaji, Satoshi Goto and Yasushi Takagi : Surgical Treatment for Combined Functional and Organic Dystonia, 第62回日本定位・機能神経外科学会, Jan. 2023.
17.	増田太利志, Shun Aoi, Makoto Kinoshita, Masahito Nakataki and Shusuke Numata : 生理的分泌物のステロイド補充によりステロイド精神病を来した一例, 第62回中国・四国精神神経学会, Nov. 2022.
18.	前田拓也, 花田直子, 岡田朝美, Yumiko Kotani, Makoto Kinoshita, Masahito Nakataki and Shusuke Numata : 先天性ホモシスチン尿症に器質性双極性感情障害を来した一症例, 第62回中国・四国精神神経学会, Nov. 2022.
19.	花田直子, 松本直樹, Makoto Kinoshita, Masahito Nakataki, Shusuke Numata and Takashi Ohmori : 電気痙攣療法が奏功した卵巣奇形腫を伴う抗NMDA受容体脳炎の1例, 第62回中国・四国精神神経学会, Nov. 2022.
20.	Masahito Nakataki, Naoki Yamada, 原田紗希 and Shusuke Numata : 希死念慮が急性期ACP(Advance Care Planning)に影響した一症例, 第35回日本総合病院精神医学会総会, Oct. 2022.
21.	Ryoma Morigaki, Kazuhisa Miyake, Taku Matsuda, Ryosuke Miyamoto, Yuishin Izumi, Masahito Nakataki and Yasushi Takagi : 機能性要素を合併したジストニアへの手術加療, 日本脳神経外科学会第81回学術総会, Sep. 2022.
22.	Tomohiko Nakayama, Ryutaro Muguruma, Saaya Tada, Mika Takahara, Ryosuke Miyamoto, Masahito Nakataki, Yuishin Izumi and Shusuke Numata : 難治性うつ病として治療中にレビー小体病が明らかとなった1症例, 第22回日本早期認知症学会学術大会, Sep. 2022.
23.	Yukiko Tomioka, Makoto Kinoshita, Tomohiko Nakayama, Hidehiro Umehara, Masahito Nakataki and Shusuke Numata : 統合失調症患者におけるDNMT1と3aの遺伝子発現量の検討, 第16回日本統合失調症学会, Mar. 2022.
24.	高尾里沙, 多田雅美, 安部修司, Masahito Nakataki, Tatsuo Mori, Toshitaka Fujihara, Yoshiteru Tada, Hiroki Yamazaki and Kenji Mori : てんかん相談における徳島県の現状の把握と今後の課題., 第9回全国てんかんセンター協議会総会鹿児島大会, Mar. 2022.
25.	Yoshiteru Tada, Masahito Nakataki, Tatsuo Mori, Toshitaka Fujihara, Aya Gohji, Hiroki Yamazaki, 高尾里沙, 泉千恵, 多田雅美, 安部修司 and Kenji Mori : 今後の徳島県におけるてんかん地域診療連携整備事業の展望について, 第9回全国てんかんセンター協議会総会, Mar. 2022.
26.	Taku Matsuda, Ryoma Morigaki, Yuki Matsumoto, Hideo Mure, Kazuhisa Miyake, Masahito Nakataki, Masafumi Harada and Yasushi Takagi : 全身性ジストニアと強迫性障害の重症度についての検討, 日本定位・機能神経外科学会機関紙, Jan. 2022.
27.	Taku Matsuda, Ryoma Morigaki, Yuki Matsumoto, Hideo Mure, Kazuhisa Miyake, Masahito Nakataki, Masafumi Harada and Yasushi Takagi : 全身性ジストニアと強迫性障害の重症度についての検討, 第61回日本定位・機能神経外科学会, Jan. 2022.
28.	六車隆太郎, 多田紗彩, Tomohiko Nakayama, Makoto Kinoshita, Masahito Nakataki and Shusuke Numata : うつ病の治療経過中にパーキンソン病の併存が明らかになった1症例, 【第61回中国・四国精神神経学会, Nov. 2021.
29.	吉田結理, Hiroaki Edo, Makoto Kinoshita, Masahito Nakataki and Shusuke Numata : 電気けいれん療法を施行した遅発性ジストニアを伴う治療抵抗性統合失調症の1症例, 第61回中国・四国精神神経学会, Nov. 2021.
30.	青木真理子, Tomohiko Nakayama, Yukiko Tomioka, Makoto Kinoshita, Masahito Nakataki and Shusuke Numata : 診断に苦慮した遅発緊張病の一例, 第61回中国・四国精神神経学会, Nov. 2021.
31.	Taku Matsuda, Ryoma Morigaki, Yuki Matsumoto, Hideo Mure, Kazuhisa Miyake, Masahito Nakataki and Yasushi Takagi : 全身性ジストニアの重症度と強迫観念の関係性についての検討, 日本脳神経外科学会学術総会, Oct. 2021.
32.	Masahito Nakataki : 認知症患者における睡眠障害のケア, 第11回日本脳血管・認知症学会総会, Aug. 2021.
33.	Ryoma Morigaki, Hideo Mure, Taku Matsuda, Kazuhisa Miyake, Ryosuke Miyamoto, Koji Fujita, Masahito Nakataki, Ryuji Kaji, Yasushi Takagi and Satoshi Goto : 機能ー器質ボーダーラインジストニアに対する脳深部刺激療法, 第60回日本定位・機能神経外科学会, Jan. 2021.
34.	Shusuke Numata, Masahito Nakataki, 長谷川尚美, Reon Edagawa, Hiroaki Edo, 三浦健一郎, 松本純弥, 稲田健, 渡邊衡一郎 and 橋本亮太 : ガイドラインの理解度向上の取り組み, 第30回日本臨床精神神経薬理学会学術総会, Jan. 2021.
35.	Ryosuke Miyamoto, 黒田一駿, Hideo Mure, Ryoma Morigaki, Masahito Nakataki, Yusuke Osaki, Yuishin Izumi, Satoshi Goto and Ryuji Kaji : 18p-症候群に伴う全身性ジストニアに対し，GPi-DBSが効果的であった一例, 第61回日本神経学会学術大会, Aug. 2020.
36.	Shusuke Numata, Masahito Nakataki, 長谷川尚美, Reon Edagawa, Hiroaki Edo, 三浦健一郎, 松本純弥, 稲田健, 渡邊衡一郎 and 橋本亮太 : 統合失調症とうつ病に対する治療ガイドライン教育プロジェクト(EGUIDEプロジェクト)におけるガイドライン理解度向上の取り組みとその結果, 第50回日本神経精神薬理学会年会, Aug. 2020.
37.	Yoshiteru Tada, Yoshihiro Touda, Masahito Nakataki, Toshitaka Fujihara, 森達夫, Aya Gohji, 飯田幸治, Kenji Mori and Yasushi Takagi : 徳島県におけるてんかん地域診療連携整備事業の活動状況, 第7回全国てんかんセンター協議会広島大会, Feb. 2020.
38.	Taku Matsuda, Ryoma Morigaki, Hideo Mure, Masahito Nakataki, 山本陽子, 豊田直人, Satoshi Goto and Yasushi Takagi : ジストニアと強迫性障害の関係についての検討, Functional Neurosurgery, 130, Jan. 2020.
39.	Ryosuke Miyamoto, Koji Fujita, Hideo Mure, Ryoma Morigaki, Masahito Nakataki, Yuishin Izumi, Satoshi Goto and Ryuji Kaji : ヒステリー性麻痺の臨床診断と電気生理心因性運動障害の診断心因性ジストニアを中心に, 第49回日本臨床神経生理学会学術大会, Nov. 2019.
40.	Masahito Nakataki, Hiroaki Edo, Yoshiteru Tada, Yoshihiro Touda, Toshitaka Fujihara, Tatsuo Mori, Aya Gohji, Kenji Mori and Tetsuro Ohmori : てんかん発作や精神症状と関連しない生活の質, 第53回日本てんかん学会学術集会, Nov. 2019.
41.	Yoshiteru Tada, Yoshihiro Touda, Masahito Nakataki, Toshitaka Fujihara, Tatsuo Mori, Aya Gohji, 飯田幸治, Kenji Mori and Yasushi Takagi : 徳島県におけるてんかん地域診療連携整備事業の紹介, 第53回日本てんかん学会学術集会, Oct. 2019.
42.	Tomoya Takeda, Masahito Nakataki, Masashi Ohta, 松浦可苗, 吉田玲於奈 and Tetsuro Ohmori : 因子分析を用いた統合失調症の神経認知機能と社会認知の検討, 日本心理学会第83回大会, Sep. 2019.
43.	Tomohiko Nakayama, Hiroaki Edo, 吉田朋広, 松本唯, Shinya Watanabe, Masahito Nakataki, Shusuke Numata and Tetsuro Ohmori : 電気けいれん療法で改善せず，ノルトリプチリンが奏功した反復性うつ病の2症例, 第16回日本うつ病学会総会, Jul. 2019.
44.	Hidehiro Umehara, 戸田裕之, 斎藤拓, Masahito Nakataki, Shusuke Numata and Tetsuro Ohmori : うつ病患者における養育環境のDNAメチル化修飾への影響の検討, 第16回日本うつ病学会総会, Jul. 2019.
45.	Makoto Kinoshita, Hidehiro Umehara, Shinya Watanabe, Masahito Nakataki, Atsushi Tajima, Shusuke Numata and Tetsuro Ohmori : 統合失調症における網羅的血漿ホモシステイン濃度関連遺伝子同定研究, 第41回日本生物学的精神医学会, Jun. 2019.
46.	青井駿, Hidehiro Umehara, Aya Gohji, 東田義広, Shinya Watanabe, Masahito Nakataki, Shusuke Numata and Tetsuro Ohmori : 感冒症状後にチック症状と強迫症状の出現増悪を認め，PANDASが疑われた1例, 第115回日本精神神経学会学術総会, Jun. 2019.
47.	Tomohiko Nakayama, 吉田朋広, Shinya Watanabe, Masahito Nakataki, Shusuke Numata and Tetsuro Ohmori : 治療に難渋し，三環系抗うつ薬で改善がみられた反復性うつ病の1例, 第115回日本精神神経学会学術総会, Jun. 2019.
48.	Takeo Tominaga, Shusuke Numata, Masahito Nakataki, Shinya Watanabe, Naomi Kameoka and Tetsuro Ohmori : 徳島大学精神医学教室の研究:認知機能・QOL, 第115回日本精神神経学会学術総会, Jun. 2019.
49.	Yukiko Tomioka, Masahito Nakataki, Hidehiro Umehara, Shinya Watanabe, Shusuke Numata and Tetsuro Ohmori : 統合失調症患者における血清葉酸濃度の検討, 第14回日本統合失調症学会, Apr. 2019.
50.	松浦可苗, Tomoya Takeda, 吉田玲於奈, Masahito Nakataki and Tetsuro Ohmori : 徳島大学病院精神科で実施された心理検査の変遷, 日本心理学会第82回大会, Sep. 2018.
51.	Masahito Nakataki, Hiroko Kubo, Satsuki Sumitani, Shusuke Numata, Naomi Kameoka, Shinya Watanabe, Hidehiro Umehara, Masashi Ohta, Masafumi Harada and Tetsuro Ohmori : 双極性障害患者におけるアミノ酸系神経伝達物質の異常, 第15回日本うつ病学会総会, Jul. 2018.
52.	Masatoshi Inoshita, Hidehiro Umehara, Shinya Watanabe, Masahito Nakataki, Makoto Kinoshita, Yukiko Tomioka, Atsushi Tajima, Shusuke Numata and Tetsuro Ohmori : うつ病患者の末梢血グルタミン酸濃度のメタ解析, 第15回日本うつ病学会総会, Jul. 2018.
53.	Hidehiro Umehara, Shinya Watanabe, Masahito Nakataki, Shusuke Numata and Tetsuro Ohmori : うつ病の末梢白血球におけるSGK1遺伝子発現, 第15回日本うつ病学会総会, Jul. 2018.
54.	Masashi Ohta, Masahito Nakataki, Tomoya Takeda, Shusuke Numata, Takeo Tominaga, Naomi Kameoka, Hiroko Kubo, Makoto Kinoshita, 松浦可苗, Maki Ohtomo, 武市直也, Masafumi Harada and Tetsuro Ohmori : 統合失調症におけるSalience Network機能障害，抑うつ気分，および主観的QOLの因果関係., 第114回日本精神神経学会学術総会, Jun. 2018.
55.	Yukiko Tomioka, Shusuke Numata, Makoto Kinoshita, Hidehiro Umehara, Shinya Watanabe, Masahito Nakataki, 岩山佳美, 豊田倫子, 池田匡志, 山森英長, 下寺信次, Atsushi Tajima, 橋本亮太, 岩田仲生, 吉川武男 and Tetsuro Ohmori : 血清ピリドキサール(ビタミンB6)と統合失調症の関連研究, 第13回日本統合失調症学会, Mar. 2018.
56.	Masashi Ohta, Masahito Nakataki, Satsuki Sumitani, Shusuke Numata, Junichi Iga, Hiroko Kubo, 田丸麻衣, 中山千明, 船越康宏, 上里彰仁, Masafumi Harada, 西川徹 and Tetsuro Ohmori : D-サイクロセリンにより治療された統合失調症患者における脳構造的および機能的結合性変化 VBMと安静時fMRIによるコンビネーション研究., 第13回日本統合失調症学会, Mar. 2018.
57.	Tomoya Takeda, Masahito Nakataki, Masashi Ohta, 濱谷沙世, 松浦可苗, 吉田玲於奈, Naomi Kameoka, Takeo Tominaga, 坂本新介, Hidehiro Umehara, Makoto Kinoshita, Hiroko Kubo, Shinya Watanabe, Shusuke Numata, Satsuki Sumitani and Tetsuro Ohmori : 統合失調症患者の否定的・肯定的自動思考と臨床要因との関連, 第13回統合失調症学会, Mar. 2018.
58.	Hideo Mure, Ryoma Morigaki, Ryosuke Miyamoto, Masahito Nakataki, Yasushi Takagi, Ryuji Kaji, Shinji Nagahiro and Satoshi Goto : ジストニアDBS治療における多職種連携．, 第57回日本定位・機能神経外科学会, Jan. 2018.
59.	Hideo Mure, Ryoma Morigaki, Ryosuke Miyamoto, Masahito Nakataki, 岡久哲也, Yasushi Takagi, Ryuji Kaji, Shinji Nagahiro and Satoshi Goto : ジストニアDBS治療における多職種連携, 第57回日本定位・機能神経外科学会, Jan. 2018.
60.	Yukio Tada, 宮崎厚子, 加藤美玲, 門田芳, 谷口早紀, Masahito Nakataki, Naomi Kameoka, Junichi Iga and Tetsuro Ohmori : がん患者を対象とした心理士による心理相談と，精神科によるリエゾン診療, 第58回中国・四国精神神経学会, Nov. 2017.
61.	Hidehiro Umehara, Shinya Watanabe, Makoto Kinoshita, Yukiko Tomioka, Masahito Nakataki, 畠山豊, 中原潔, Takeshi Nikawa, Shusuke Numata and Tetsuro Ohmori : うつ病における血漿グルタミン，グルタミン酸，グルタミン/グルタミン酸比, 第27回日本臨床精神神経薬理学会, Nov. 2017.
62.	Hideo Mure, Ryoma Morigaki, Ryosuke Miyamoto, Masahito Nakataki, Junichiro Satomi, Ryuji Kaji, Satoshi Goto and Shinji Nagahiro : ジストニアDBS治療におけるチーム医療の重要性 -徳島大学での取り組み-, 日本脳神経外科学会第76回学術総会, Oct. 2017.
63.	Masahito Nakataki, Leila M. Soravia, Simon Schwab, Helge Horn, Thomas Dierks, Werner Strik, Roland Wiest, Markus Heinrichs, Dominique J.-F. de Quervain, Andrea Federspiel and 森島洋介 : クモ恐怖症患者の恐怖刺激の処理に関与する神経ネットワークにおけるグルココルチコイドの効果, 第39回日本生物学的精神医学会, Sep. 2017.
64.	Tomoya Takeda, Masahito Nakataki, Masashi Ohta, 濱谷沙世, 松浦可苗 and Tetsuro Ohmori : 統合失調症患者における神経認知機能を媒介した脳灰白質体積とQOLの関連., 第39回日本生物学的精神医学会, Sep. 2017.
65.	松浦可苗, 濱谷沙世, Tomoya Takeda, Masahito Nakataki and Tetsuro Ohmori : ASD精査目的で行われたWAIS-ⅢとPARS-TRとの関連, 第81回日本心理学会, Sep. 2017.
66.	Masatoshi Inoshita, Makoto Kinoshita, Hidehiro Umehara, Masahito Nakataki, Atsushi Tajima, 池田匡志, 丸山惣一郎, 山森英長, 金沢徹文, 下寺信次, 橋本亮太, Issei Imoto, 米田博, 岩田仲生, Shusuke Numata and Tetsuro Ohmori : C-reactive protein and schizophrenia; A Mendelian Randomization approach., 第12回日本統合失調症学会, Mar. 2017.
67.	Hiroko Kubo, Masahito Nakataki, Satsuki Sumitani, Masafumi Harada and Tetsuro Ohmori : MRSを用いた気分安定薬服用中の双極性障害患者におけるグルタミン酸神経伝達の異常, 第26回日本臨床精神神経薬理学会, Nov. 2016.
68.	Masahito Nakataki : 神経回路機能異常 -病態と治療- シンポジウム恐怖症患者の神経ネットワーク異常とコルチゾール投与による変化, 第59回脳循環代謝学会, Nov. 2016.
69.	Masashi Ohta, Masahito Nakataki, Mai Tamaru, Hiroko Kubo, 中山千明, 船越康宏, 上里彰仁, Shusuke Numata, Junichi Iga, Satsuki Sumitani, Masafumi Harada, 西川徹 and Tetsuro Ohmori : D-サイクロセリンにより治療された統合失調症患者における内側前頭前皮質の機能的統合安静時fMRI研究, 第46回日本神経精神薬理学会, Jul. 2016.
70.	Hiroko Kubo, Masahito Nakataki, Satsuki Sumitani and Tetsuro Ohmori : MRSによる双極性障害におけるリチウムの作用の検討., 第24回日本臨床精神神経薬理学会, Nov. 2014.
71.	Junichi Iga, Shinya Watanabe, Akira Nishi, Shusuke Numata, Makoto Kinoshita, Kumiko Kikuchi, Masahito Nakataki and Tetsuro Ohmori : Microarray analysis of the leukocyte global gene expression profile following lithium treatment., Neuro 2013(第36回日本神経科学大会・第56回日本神経化学会大会・第23回日本神経回路学会大会, Jun. 2013.
72.	Ryoma Morigaki, Masahito Nakataki, Junichi Iga, Toshitaka Kawarai, Hideo Mure, Yoshifumi Mizobuchi, 大北真哉, Tetsuro Ohmori, Shinji Nagahiro, Satoshi Goto and Ryuji Kaji : X-linked dystonia-parkinsonismのうつ症状, 第52回日本定位・機能神経外科学会, Jan. 2013.
73.	Tetsuro Furumoto, Kojiro Nagai, Satoshi Yamada, Eriko Shibata, Fumi Kishi, Seiji Kishi, Motokazu Matsuura, Akira Mima, Hideharu Abe, Toshio Doi, Risa Takeuchi, Ysuhiro Noda, Seiji Kobayashi, Yusuke Chikata, Aiko Takamatsu, Kanae Yamada, 長江雄浩 and Masahito Nakataki : 血液透析によってリチウム中毒による意識障害の改善をみた1症例, 第43回徳島透析療法研究会, Nov. 2012.
74.	Masahito Nakataki, 渡部真也, 福間亮介, Junichi Iga and Tetsuro Ohmori : クロザピンにより薬剤性ジストニアが改善した2症例, 第22回日本臨床精神神経薬理学会・第42回日本神経精神薬理学会合同年会, Oct. 2012.
75.	Junichi Iga, Shinya Watanabe, 西晃, Shusuke Numata, Makoto Kinoshita, Masahito Nakataki and Tetsuro Ohmori : 白血球遺伝子発現を指標としたリチウムの精神薬理学的研究, 第22回日本臨床精神神経薬理学会, Oct. 2012.
76.	Makoto Kinoshita, Masahito Nakataki, Satsuki Sumitani and Tetsuro Ohmori : 片側電極のOn-Offによって躁状態とうつ状態を呈した両側STN-DBSを施行されたパーキンソン病の一例, 第34回日本生物学的精神医学会, Sep. 2012.
77.	Masahito Nakataki and Tetsuro Ohmori : 統合失調症患者におけるグルタミン酸・GABAの動態, 第34回日本生物学的精神医学会, Sep. 2012.
78.	福間亮介, Masahito Nakataki, Junichi Iga and Tetsuro Ohmori : 重篤な遅発性ジストニアを持つ統合失調症患者へclozapineを用いた一例, 第52回中国・四国精神神経学会, Nov. 2011.
79.	Makoto Kinoshita, Masahito Nakataki, Satsuki Sumitani and Tetsuro Ohmori : 両側視床下核深部脳刺激術を施行され左側電極Onによってうつ状態から躁状態に転じたパーキンソン病の一例, 第52回中国・四国精神神経学会, Nov. 2011.
80.	Masahito Nakataki, Hiroko Kubo, Junichi Iga, Shinya Watanabe, Satsuki Sumitani, Masafumi Harada and Tetsuro Ohmori : 統合失調症患者におけるアミノ酸神経伝達が抗精神病薬から受ける影響 1H-MRS(proton magnetic resonance spectroscopy)を用いた検討, 第21回日本臨床精神神経薬理学会・第41回日本神経精神薬理学会合同年会, Oct. 2011.
81.	Junichi Iga, 菊池久美子, Sumiko Tayoshi, Masahito Nakataki, 渡部真也, Shusuke Numata and Tetsuro Ohmori : SOCS3遺伝子はリチウムの作用機序とうつ病の病態における候補遺伝子である, 第21回日本臨床精神神経薬理学会, Oct. 2011.
82.	渡部真也, Junichi Iga, Masahito Nakataki, Shusuke Numata, 菊地久美子 and Tetsuro Ohmori : 統合失調症患者と健常対象者におけるFTO遺伝子とbody mass indexとの関連研究, 第21回日本臨床精神神経薬理学会, Oct. 2011.
83.	Satsuki Sumitani, Shinya Tayoshi, Masahito Nakataki and Tetsuro Ohmori : 高磁場MRSを用いた非侵襲的脳内代謝物質測定による統合失調症アミノ酸仮説の検討, 第7回統合失調症研究会, Feb. 2011.
84.	Masahito Nakataki, Shusuke Numata, Ken Yamauchi, 元木洋介, 宇山環奈, 青野成孝, Takeo Tominaga, Yasuhiro Kaneda and Tetsuro Ohmori : 初発，再発の統合失調症患者におけるアリピプラゾールの有用性の検討多施設共同臨床研究, 第20回日本臨床精神神経薬理学会, 2010.
85.	Shinya Watanabe, Junichi Iga, Masahito Nakataki, Kumiko Kikuchi and Tetsuro Ohmori : 日本人におけるcannabinoid receptor1 遺伝子多型とbody mass index,および統合失語症との関連研究, 第32回日本生物学的精神医学会, Oct. 2010.
86.	Masahito Nakataki, Shinya Tayoshi and Tetsuro Ohmori : 画像研究は統合失調症の病態をどこまで明らかにしたか?, 第32回日本生物学的精神医学会, Oct. 2010.
87.	Masahito Nakataki and Tetsuro Ohmori : 統合失調症研究におけるMRS, 第32回日本生物学的精神医学会, Oct. 2010.
88.	福田正人, 高橋英彦, 岡田剛, Masahito Nakataki, 滝沢龍 and 中村元昭 : 脳画像から見た精神薬理-マクロとミクロの接点, 第20回日本臨床精神神経薬理学会, Sep. 2010.
89.	Junichi Iga, 菊地久美子, Masahito Nakataki, Shinya Watanabe, Shusuke Numata and Tetsuro Ohmori : Lithium decreases VEGF mRNA expression in leukocytes of healthy subjects and bipolar patients, 第20回日本臨床精神神経薬理学会, Sep. 2010.
90.	Yoshinori Ueoka, Masahito Tomotake, Tsunehiko Tanaka, Yasuhiro Kaneda, Masahito Nakataki, Shusuke Numata, Shinya Tayoshi, Satsuki Sumitani, Takashi Ohmori, Shu-ichi Ueno and Tetsuro Ohmori : Subjective Quality of Life and Cognitive Function in Outpatients with Schizophrenia, 第5回日本統合失調症学会, Mar. 2010.
91.	Yoshinori Ueoka, Masahito Tomotake, Tsunehiko Tanaka, Yasuhiro Kaneda, Masahito Nakataki, Satsuki Sumitani, Shu-ichi Ueno and Tetsuro Ohmori : Quality of Life and Cognitive Dysfunction in People with Schizophrenia, 第19回日本臨床精神神経薬理学会・第39回日本神経精神薬理学会合同年会, Nov. 2009.
92.	Masahito Tomotake, Yoshinori Ueoka, Tsunehiko Tanaka, Yasuhiro Kaneda, Ken Yamauchi, Kyoko Taniguchi, Takikawa Yumiko, Masahito Nakataki, Shusuke Numata, Shinya Tayoshi, Satsuki Sumitani, Yumiko Izaki, Takashi Ohmori, Shu-ichi Ueno and Tetsuro Ohmori : Quality of life and cognitive function in outpatients with schizophrenia, 第18回日本臨床精神神経薬理学会・第38回日本神経精神薬理学会合同年会, Oct. 2008.
93.	Yoshinori Ueoka, Masahito Tomotake, Tsunehiko Tanaka, Yasuhiro Kaneda, Masahito Nakataki, Shusuke Numata, Shinya Tayoshi, Satsuki Sumitani, Yumiko Izaki, Takashi Ohmori, Shu-ichi Ueno and Tetsuro Ohmori : Relationship between cognitive function and clinical factors in people with schizophrenia, 第18回日本臨床精神神経薬理学会・第38回日本神経精神薬理学会合同年会, Oct. 2008.
94.	Shusuke Numata, Masahito Nakataki, Junichi Iga, Toshihito Tanahashi, Mitsuo Itakura, Shu-ichi Ueno and Tetsuro Ohmori : 日本人におけるうつ病患者のPCNT2遺伝子関連解析, 第30回日本生物学的精神医学会, Sep. 2008.
95.	Masahito Nakataki, Shu-ichi Ueno, Shusuke Numata, Junichi Iga, Shinya Tayoshi, Sumiko Tayoshi, 宋鴻偉, Toshihito Tanahashi, Mitsuo Itakura and Tetsuro Ohmori : 統合失調症とRho-associated coiled-coil forming protein serine/threonine kinase1遺伝子の関連解析, 第30回日本生物学的精神医学会, Sep. 2008.
96.	Shusuke Numata, Junichi Iga, Shu-ichi Ueno, Ken Yamauchi, Hongwei Song, Sumiko Tayoshi, Shinya Tayoshi, Masahito Nakataki, Ryota Hashimoto, Masatoshi Takeda, Hiroshi Kunugi and Tetsuro Ohmori : Differential expression of Disrupted-In-Schizophrenia-1 (DISC1) in the peripheral leukocytes from schizophrenia and major depressive disorder, The 2nd Annual Meeting of Japanse Society of Schizophrenia Research, Mar. 2007.

Products:

1.	Masahito Nakataki : 精神疾患と自殺予防, めんたるへるす, No.68, 6-10, Feb. 2020.

Et cetera, Workshop:

1.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Akira Takahashi, 岡本泰昌 and Shusuke Numata : 双極性障害における血中メタボローム解析, 第42回躁うつ病の薬理・生化学的研究懇話会, Oct. 2023.
2.	Masahito Nakataki : 精神症状による脱力が疑われた重症筋無力症を併発した統合失調症の症例, 第30回中国四国地区GHP研究会, Sep. 2023.
3.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Akira Takahashi, 岡本泰昌 and Shusuke Numata : 双極性障害における血中代謝物の変化, 第13回脳科学クラスターミニリトリート, Feb. 2022.
4.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Shusuke Numata, Akira Takahashi, 岡本泰昌 and Tetsuro Ohmori : うつ病におけるキヌレニン経路の変化, 第40回躁うつ病の薬理・生化学的研究懇話会, Oct. 2021.
5.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Shusuke Numata, Akira Takahashi, 岡本泰昌 and Tetsuro Ohmori : うつ病におけるキヌレニン経路の変化, 第12回脳科学クラスターミニリトリート, Feb. 2021.
6.	Tomohiko Nakayama, Hidehiro Umehara, Yukiko Tomioka, 上敷領俊晴, 淵上学, 岡田剛, 増田瑠見子, Kazuaki Mawatari, Masahito Nakataki, Shusuke Numata, Akira Takahashi, 岡本泰昌 and Tetsuro Ohmori : うつ病におけるキヌレニン経路の変化, 第5回メタボロームシンポジウム, Dec. 2020.
7.	Tomoya Takeda, Masahito Nakataki, Masashi Ohta and Tetsuro Ohmori : 統合失調症患者における結論への飛躍バイアスと神経認知，社会認知との関連, 第10回脳科学クラスター・ミニリトリート, Feb. 2019.
8.	Tomoya Takeda, Masahito Nakataki, Masashi Ohta and Tetsuro Ohmori : 統合失調症患者における自己に関する認知と主観的・客観的QOLとの関連., 第18回精神疾患と認知機能研究会, Nov. 2018.
9.	武田知也, Masahito Nakataki, Masashi Ohta, 濱谷沙世, 松浦可苗, 吉田玲於奈, Naomi Kameoka, Takeo Tominaga, 坂本新介, Hidehiro Umehara, Makoto Kinoshita, Hiroko Kubo, Shinya Watanabe, Shusuke Numata, Satsuki Sumitani and Tetsuro Ohmori : 統合失調症患者における神経認知機能と否定的・肯定的認知の関連., 第4回CEPD会, Mar. 2018.
10.	Tomoya Takeda, Masahito Nakataki, Masashi Ohta, 濱谷沙世, 松浦可苗 and Tetsuro Ohmori : Jumping to conclusionバイアスと認知機能との関連, 第17回精神疾患と認知機能研究会, Nov. 2017.
11.	Hidehiro Umehara, Shinya Watanabe, Makoto Kinoshita, Yukiko Tomioka, Masahito Nakataki, 畠山豊, 中原潔, Takeshi Nikawa, Shusuke Numata and Tetsuro Ohmori : うつ病のメタボローム解析, 第2回メタボローム解析シンポジウム, Jun. 2017.
12.	Tomoya Takeda, Masahito Nakataki, Masashi Ohta, Sayo Hamatani and Tetsuro Ohmori : 結論への飛躍バイアスや決断への自信と認知機能との関連, 第3回CEPD研究会, Mar. 2017.
13.	Shusuke Numata, Masahito Nakataki, Junichi Iga, Shinya Tayoshi, 谷口京子, Satsuki Sumitani, Masahito Tomotake and 他 : 大うつ病の末梢白血球におけるPDE4B遺伝子の発現と関連研究, 第41回精神神経系薬物治療研究報告会, Dec. 2008.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

A study of the relationship between cerebral quantitative susceptivility mapping and cerebral blood flow in patients with Alzheimer's disease. (Project/Area Number: 24K10735 )
Evaluation of genetic polymorphisms and 3T H-MRS in OCO (Project/Area Number: 19790820 )
Search by Researcher Number (20448335)

Associate Professor : Nakataki, Masahito

Research

Field of Study

Subject of Study

Book / Paper

Book:

Academic Paper (Judged Full Paper):

Academic Paper (Unrefereed Paper):

Academic Letter:

Review, Commentary:

Proceeding of International Conference:

Proceeding of Domestic Conference:

Products:

Et cetera, Workshop:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)